3,619 Matching Annotations
  1. Last 7 days
    1. Patient 3

      Case#: Patient 3, female, symptoms began at birth, diagnosed at 5 weeks

      DiseaseAssertion: Pompe Disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639, HP:0003712 (hypertrophic cardiomyopathy, hypertrophy of calves)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: <1% normal GAA expression in fibroblast; after ERT treatment had 100% enzyme activity in cell lysates; unclear how patient was diagnosed

      Variant 1: NM_000152.5:c.525delT

      Variant 1 ClinVarID: 4033

      Variant 1 CAid: CA220406

      Variant 2: NM_000152.5:c.525delT

      Variant 2 ClinVarID: 4033

      Variant 2 CAid: CA220406

      ParentalGenotype: Not provided

    1. 18

      Case#: Subject number 18(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 542 U/L (60-305 U/L is normal), AST: 152 U/L (22-71 U/L is normal), ALT: 55 U/L (7-50 U/L is normal), Hex4: 7.6 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal), BNP 16.5 pg/mL (0.0–100.0 pg/mL is normal)

      glucosidase activity: GAA activity #1 was 0.7 micromole/L/h and GAA activity #2 (NBS) 0.34 in dried blood spots (>2.10 micromole/L/h is normal). 1.40 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.2560C>T

      Variant 2 ClinVarID: 4034

      Variant 2 CAid: CA340130

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. 9

      Case#: Subject number 9(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 145 U/L (60-305 U/L is normal), AST: 72 U/L (22-71 U/L is normal), ALT: 43 U/L (7-50 U/L is normal), Hex4: 5.3 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal), BNP 13.0 pg/mL (0.0–100.0 pg/mL is normal)

      glucosidase activity: GAA activity #1 was 0.97 micromole/L/h and GAA activity #2 (NBS) 0.33 in dried blood spots (>2.10 micromole/L/h is normal). 0.93 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.2238G>C

      Variant 1 ClinVarID: 265160

      Variant 1 CAid: CA8815665

      Variant 2: NM_000152.5(GAA):c.2281delGinsAT

      Variant 2 ClinVarID: 370993

      Variant 2 CAid: CA16041905

      Variant 3: NM_000152.5(GAA):c.2065G>A

      Variant 3 ClinVarID: 4030

      Variant 3 CAid: CA116612

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. 4

      Case4: Female, 16 years diagnosis, 13 years onset

      CasePresentingHPOs: HP:0009073, HP:0003198, HP:0003236, HP:0003327, HP:0008994 (Progressive proximal muscle weakness, Myopathy, Increased serum CK, Axial muscle weakness, Proximal muscle weakness in lower limbs)

      HPOsFreeText: Electromyography showed myogenic damage, Vacuolar myopathy, Serum CK is 1652.0 U/L

    1. 3

      Case#: Patient 3, Female, 2 months old at diagnosis, Caucasian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001252, HP:0001638

      (Muscular hypotonia, Cardiomyopathy)

      CaseHPOFreeText: floppy baby, no head or neck control

      NG tube feeds started at age 1.4 months, currently the patient orally feeds.

      Before ERT patient needed oxygen, currently the patient does not need respiratory support.

      CaseNotHPOs:

      CaseNotHPOFreeText:

      Patient ambulates independently

      No infusion associated reactions to ERT

      CasePreviousTesting: No GAA measurement

      Variant: NM_000152.5(GAA):c.236_246del (p.Pro79fs)

      ClinVar: 371302

      CAID: CA16041880

      gnomAD: N/A

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. 9

      Patient9: Male

      CasePresentingHPOs: HP:0004887, HP:0002194, HP:0001522

      HPOsFreeText: ERT dosage = 20 mg/kg/2 w, CRIM negative

      CaseNotHPOs:

      NotHPOsFreeText: no HCM reversal

      CaseAddInfo: Symptom onset at 2mo, diagnosis at 4mo, ERT at 4.5mo, ERT lasted for 4mo, ventilation required at 7mo, died at 10mo

      CasePMIDs: 22252923, 27629047

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1657C>T

      CAID: CA401368835, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1657C%3ET

      gnomAD: n/a

    1. #8

      Case#: Subject number 8, female, 32 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: No known family member with PD

      CasePresentingHPOs: HP:0002153 (hyperkalemia), HP:0001324 (muscle weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0001638 (cardiomyopathy), HP:0003546 (Exercise intolerance), HP:0001252 (Hypotonia), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0002098 (respiratory distress), HP:0002094 (dyspnoea)

      CaseNotHPOFreeText: no biopsy, not asymptomatic

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.3 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.925G>A (p.Gly309Arg)

      Variant 2 ClinVarID: 188797

      Variant 2 CAid: CA273972

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. #13

      Case#: Subject number 13, female, 57 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: No known family member with PD

      CasePresentingHPOs: HP:0001324 (muscle weakness), HP:0003546 (Exercise intolerance), HP:0002094 (dyspnoea)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0001252 (Hypotonia), HP:0001638 (cardiomyopathy), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0002153 (hyperkalemia), HP:0002098 (respiratory distress)

      CaseNotHPOFreeText: no biopsy, not asymptomatic

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.37 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.2237G>C (p.Trp746Ser)

      Variant 2 ClinVarID: 188484

      Variant 2 CAid: CA198797

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. PD21

      Patient21: Female, Northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1802C>T (p.Ser601Leu)

      ClinVar: 194154, https://www.ncbi.nlm.nih.gov/clinvar/variation/194154/

      gnomAD: n/a

      Variant2: NM_000152.3:c.1844G>T

      CAID: CA401369601, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401369601

      gnomAD: n/a

    2. PD24

      Patient24: Female, Northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: c.1151 + 2T > G no ClinVar or CAID, intronic position inside exon

      Variant2: NM_000152.3:c.1562A>T

      CAID: CA401367205, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401367205

      gnomAD: 0.000003980, http://gnomad.broadinstitute.org/variant/17-78084750-A-T

    1. 20 mg/kg (N = 16)

      Case12HPOsFreeText: 20 mg/kg GAA treatment, GAA activity at 4 nmol/punch/hr, GAA activity at 15% lower limit of normal

      CaseAddInfo: Late Onset Pompe Disease


      CaseGenotypingMethod: Method not described, only that the diagnosis was "confirmed … based on 2 GAA gene mutations"


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 https://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.546+1G>T

      CAID: CA401361913 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.546%2B1G%3ET

      gnomAD: Not in gnomAD


      CaseAddInfo:

    1. PD/VOUS-5

      CasePD/VOUS-5: 1.7 years diagnosis

      HPOsFreeText: GAA activity 9.16 (nmol · h−1 · mg−1), Mean percentage of normal 12.9%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.2065G>A (p.Glu689Lys)

      ClinVar: 4030 https://www.ncbi.nlm.nih.gov/clinvar/variation/4030/

      gnomAD: East Asian 0.2355, Overall 0.05524 http://gnomad.broadinstitute.org/variant/17-78087041-G-A


      Variant3: NM_000152.4:c.1424C>T (p.Pro475Leu)

      CAID: CA8815314 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3:c.1424C%3ET

      gnomAD: South Asian 1.307e-4, Overall 2.009e-5 http://gnomad.broadinstitute.org/variant/17-78083841-C-T


      CaseAddInfo: Patient has one pseudodeficency allele and one allele of uncertain significance, Nomenclature claims Variant 1 and 2 are in cis

    1. CaseLP-2: Female, Taiwan, Birth diagnosis

      HPOsFreeText: 4MU enzyme activity at 0.85, MS/MS ennzyme activity at 0.42

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.671G>A (p.Arg224Gln)

      CAID: CA8814958 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.671G%3EA

      gnomAD: African 8.060e-5, Overall 2.549e-5 http://gnomad.broadinstitute.org/variant/17-78079672-G-A


      Variant2: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant3: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      CaseAddInfo: Suspected Late Onset Pompe Disease, Nomenclature indicates Variants 2 and 3 are in cis

    2. CaseOPOPD-5: Female, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.97 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.503G>C (p.Arg168Pro)

      CAID: CA401361673 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.503G%3EC

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      CaseAddInfo: One Pompe Mutation and One Pseudodeficency Mutation

    1. 7

      Case#: Patient 7

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None

      CaseHPOFreeText: None

      CaseNotHPOs: None

      CaseNotHPOFreeText: None

      CasePreviousTesting: Single gene sequencing with Ion Torrent Persional Genome Machine

      Glucosidase activity: 0.05 nmol 5MU/hr/mL

      Variant 1: NM_000152.5:c.2560C>T

      Variant 1 ClinVarID: 4034

      Variant 1 CAid: CA340130

      Variant 2: NM_000152.5:c.596A>G

      Variant 2 ClinVarID: 92486

      Variant 2 CAid: CA145785

      Variant 3: NM_000152.5:c.668G>A

      Variant 3 ClinVarID: 92488

      Variant 3 CAid: CA145791

      ParentalGenotype: Not provided

    1. 5

      Case#: P 5, Male, 0.9 months old when started ERT (76.9 months old at publication date), Ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0006532

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Recurrent pneumonia)

      CaseHPOFreeText: Recurrent pneumonia was a complication during ERT.

      AR III

      Patient requires tube feeding and is ventilated

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CRIM status is unknown

      Antibody titer is 1:12,000

      Variant: NM_000152.5(GAA):c.2662G>T (p.Glu888Ter)

      ClinVar: 578595

      CAID: CA8815829

      gnomAD: Highest population MAF= 0.0002719 (East asian)

      ParentalGenotype: Both the paternal and maternal allele carry the c.2662G>T (p.Glu888Ter) Variant

      PreviouslyPublished: N/A

    1. C

      Case3: Patient ID C, Male, 12 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Hematoma

      CaseNotHPOs: HP:0000967, HP:0000979, HP:0000978, HP:0004406, HP:0000225, HP:0002239, HP:0002239, HP:0000790, HP:0005261, HP:0002248

      (Petechiae, purpura, easy bruising, recurrent epistaxis, gingival bleeding, gastrointestinal bleeding, intracranial hemorrhage, hematuria, hemarthrosis, hematemesis)

      CaseNotHPOsFreeText: Hemhorrage after dental, hemhorrage after trauma, ear bleeding

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify a;; coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1233C>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399803781

      gnomAD: N/A

      PreviouslyPublished: PMID: 12424194

    2. J

      Case10: Patient ID J, Female, 5 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Related to Patient's I and K (See Table 1)

      ParentalGenotype: N/A (Parents are consangenous)

      CasePresentingHPOs: HP:0000978, HP:0004406, HP:0000225, HP:0002239

      (Easy bruising, recurrent epistaxis, gingival bleeding, GI bleeding

      CaseHPOFreeText: Hemorrhage after trauma, hematoma

      CaseNotHPOs: HP:0000967, HP:0000979, HP:0002239, HP:0000790, HP:0005261, HP:0002248

      (Petechiae, purpura, intracranial hemorrhage, hematuria, hemarthrosis, hematemesis)

      CaseNotHPOsFreeText: Hemorrhage after dental, ear bleeding

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1652G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602986

      gnomAD: MAF in South Asian population is 0.00006536 http://gnomad.broadinstitute.org/variant/17-42457470-C-T

      PreviouslyPublished: PMID: 19172520

    1. Family L

      Case15: Family L (patient found in the GT database as well) gender and age are not specified here

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225(Epistaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

      PreviouslyPublished: Reference numbers 26,27 in this article

    2. Mila-1

      Case8: Patient Mila-1 (found in the GT database) gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 25% GPIIIa and GPIIb surface expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His)

      LegacyVariant: N/A

      ClinVar: 2896

      CAiD: CA115839

      gnomAD: N/A

      PreviouslyPublished: Reference number 19 in this article

    3. GT3

      Case33: Patient GT3

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.777+1G>A and the second variant I am not sure how to write out

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623036

      gnomAD: MAF in the Latino population is 0.0006774 https://gnomad.broadinstitute.org/variant/17-45363789-G-A

      PreviouslyPublished: References 53-55

    4. CW

      Case12: Patient CW (can be found in GT database) gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0031364, HP:0000979, HP:0000967, (Ecchymosis, Purpura/petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: <1% of normal GPIIIa and GPIIb surface expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter) and NM_000419.3:c.480C>G (p.Ser160_102del)

      LegacyVariant: N/A

      ClinVar: 2892 (Arg584Ter)

      CAiD: CA115834 and CA399805892

      gnomAD: MAF in the East Asian population is 0.0002176 for the Arg584Ter variant and MAF in the East Asian population is 0.00005507 for the other variant https://gnomad.broadinstitute.org/variant/17-42463013-G-C

      PreviouslyPublished: Reference number 23 in this article

    5. I-J1

      Case38: Patient IJ12

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: HP:0000421, HP:0000225, HP:0002239, HP:0000979, HP:0000967, HP:0006298

      (Epistaxis, gingival bleeding, GI bleeding, purpura/petechiae, prolonged bleeding after tooth extraction)

      CaseNotHPOsFreeText: N/A

      ProteinExpression: <2% GPIIIa and GPIIb surface expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.2031_2041del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940605

      gnomAD: N/A

      PreviouslyPublished: References 8-12

    1. Supplementary Table S1 & S2 Proband and Variant Information:

      Case19: GT22, Male, 13, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000225

      (Easy bruising, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.408+11C>A and NM_000419.3:c.1259T>C (p.Val420Ala)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940333 and CA399803733

      gnomAD: N/A

    2. Supplementary Table S1 & S2 Proband and Variant Information:

      Case17: GT20, Male, 28, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0005261

      (Epistaxis, hemarthrosis)

      CaseHPOFreeText: Occasional hematomas

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed 10-20% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.2800G>T (p.Val934Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290946484

      gnomAD: N/A

    3. Supplementary Table S1 & S2 Proband and Variant Information:

      Case64: GT67, Male, 61 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother who is now dead (this is all the information we are provided with)

      ParentalGenotype: N/A

      CasePresentingHPOs:

      (Gingival bleeding, epistaxis, bleeding after dental extraction )

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1440-13_1440-1del (p.Arg480Serfs*106) and NM_000419.3:c.1618C>T (p.Gln540Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913184940 and CA399802411

      gnomAD: MAF in the African population is 0.000 https://gnomad.broadinstitute.org/variant/17-42457504-G-A

    4. Supplementary Table S1 & S2 Proband and Variant Information:

      Case27: GT31, Female, 13, USA

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0000421

      (Gingival bleeding and epistaxis)

      CaseHPOFreeText: Life-threatening bleeding at onset of menses

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed 5-10% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1771dup (p.Asp591Glyfs*47) and NM_000419.3:c.3061-1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940334 and CA399787972

      gnomAD: N/A

    5. Supplementary Table S1 & S2 Proband and Variant Information:

      Case69: GT73, Female, 34 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0031364, HP:0000421, HP:0000225, HP:0000132

      (Ecchymosis, epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed nromal to reduced αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.889G>A (p.Gly297Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623074

      gnomAD: MAF in the European (non-Finnish) population is 0.00002643 https://gnomad.broadinstitute.org/variant/17-45364547-G-A

    6. Supplementary Table S1 & S2 Proband and Variant Information:

      Case1: GT1, Male, 9, French/African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0011890, HP:0000421, HP:0000225

      (Bruising susceptibility, prolonged bleeding following procedure, epistaxis, gingival bleeding)

      CaseHPOFreeText: Tonsilar hemorrhage

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.1913+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400032825

      gnomAD: N/A

    7. Supplementary Table S1 & S2 Proband and Variant Information:

      Case44: GT43b, Male, 11 years old, Morrocan

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister is 43a (See Supplementary Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000979, HP:0031364, HP:0000967, HP:0030137

      (Epistaxis, purpura, ecchymosis, petechiae, prolonged bleeding at circumcision)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.614+1G>T and NM_000212.2:c.683G>A (p.Arg228His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023344 and CA8623025

      gnomAD: MAF in the African population is 0.00008012 http://gnomad.broadinstitute.org/variant/17-45363694-G-A

    8. Supplementary Table S1 & S2 Proband and Variant Information:

      Case56: GT57, Female, 10, Argentinian/European

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000967

      (Epistaxis, petechia)

      CaseHPOFreeText: Hematomas

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.571T>G (p.Phe191Val) and NM_000419.3:c.961G>T (p.Phe191Alafs*32)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805699 and CA399804768

      gnomAD: N/A

    9. Supplementary Table S1 & S2 Proband and Variant Information:

      Case44: GT43b, Male, 11 years old, Morrocan

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister is 43a (See Supplementary Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000979, HP:0031364, HP:0000967

      (Epistaxis, purpura, ecchymosis, petechiae)

      CaseHPOFreeText: Lots of bleeding at circumcision

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.614+1G>T and NM_000212.2:c.683G>A (p.Arg228His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023344 and CA8623025

      gnomAD: MAF in the African population is 0.00008012 http://gnomad.broadinstitute.org/variant/17-45363694-G-A

    1. NA

      Case13: Patient NA

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: There is a typo in this article, the article states Glu500Ter however it is Gln. NM_000419.3:c.1591C>T (p.Gln531Ter)

      LegacyVariant: (p.Gln500Ter)

      ClinVar: N/A

      CAiD: CA399802478

      gnomAD: N/A

    1. 12.

      Case12: 2 Females, age not specified "Two sisters" is what the Table mentions

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0002239

      (Gastrointestinal bleeding)

      CaseHPOFreeText: Life threatening bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting:

      Gene: ITGB3 and ITGA2B

      Variant: NM_000212.2:c.392G>C (p.Arg131Pro in ITGB3) and NM_000212.2:c.777+1G>A in ITGB3 and NM_000419.3:c.2264G>A (p.Arg755Gln) in ITGA2B

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622954, CA8623036, CA8602771

      gnomAD: MAF in the African population 0.00006152 http://gnomad.broadinstitute.org/variant/17-45361839-G-C , MAF in Latino population 0.0006774 http://gnomad.broadinstitute.org/variant/17-45363789-G-A and MAF in Latino population 0.0001903 (p.Arg775Gln)

    2. 24.

      Case24: Male, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe bleeding (See Table 1 for Clinical and Biological Data-- minimal information)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3

      Variant: NM_000212.2:c.1619G>A (p.Gly540Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400030071

      gnomAD: N/A

    3. 10.

      Case10 : Female, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3

      Variant: NM_000212.2:c.940G>T (p.Asp314Tyr)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400025612

      gnomAD: N/A

    1. Supplementary Tables 1 and 2 combined information:

      Case20b: GT20b, Female, 23 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Family information available in Table1 (sister of proband GT20a)

      ParentalGenotype: Parents are consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0002239, HP:0000132

      (Bruising, purpura, ecchymosis, gastrointestinal bleeding, menorrhagia)

      CaseHPOFreeText: Post traumatic bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399801310

      gnomAD: MAF in Latino population: 0.00003983 https://gnomad.broadinstitute.org/variant/17-42456075-G-A

    2. Supplementary Tables 1 and 2 combined information:

      Case35: GT35, Male, 1 year old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364

      (Bruising, purpura, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.625-1G>A (c.625-1G>A) and NM_000419.3:c.659A>G (p.Tyr220Cys)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805552 (c.625-1G>A) and CA399805484 (p.Tyr220Cys)

      gnomAD: MAF for (p.Tyr220Cys) in the South Asian population 0.00003266 https://gnomad.broadinstitute.org/variant/17-42462543-T-C

    3. Supplementary Tables 1 and 2 combined information:

      Case26: GT26, Male, 13 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364

      (Bruising, purpura, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (Gln778Pro) and NM_000419.3:c.2671C>T (p.Gln891Ter)

      LegacyVariant: N/A

      ClinVar: 225393 (p.Gln778Pro)

      CAiD: CA290947544 (p.Gln778Pro) and CA8602626 (p.Gln891Ter)

      gnomAD: MAF in East Asian population: 0.0001087 https://gnomad.broadinstitute.org/variant/17-42453691-T-G

    4. Supplementary Tables 1 and 2 combined information:

      Case12: GT12, Male, 10 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Family history available per Table 1; however, no further information given

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro)

      LegacyVariant: N/A

      ClinVar: 225393

      CAiD: CA290947544

      gnomAD: N/A

    5. Supplementary Tables 1 and 2 combined information:

      Case29: GT29, Female, 16 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000132, HP:0000978, HP:0000979, HP:0031364, HP:0000225

      (Menorrhagia, bruising, purpura, ecchymosis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in the East Asian population: 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    6. Supplementary Tables 1 and 2 combined information:

      Case22: GT22, Female, 16 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000132 (Menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in the East Asian population: 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    7. Supplementary Tables 1 and 2 combined information:

      Case4: GT4, Female, 22 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421, HP:0000225, HP:0000132

      (Bruising, purpura, ecchymosis, epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2671C>T (p.Gln891Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602626

      gnomAD: N/A

    8. Supplementary Tables 1 and 2 combined information:

      Case41: GT41, Male, 5 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGB3

      Variant: NM_000212.2:c.1736G>A (p.Trp579Ter) and NM_000212.2:c.1784_1802delinsGTCACA

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400032429 (p.Trp579Ter) and CA915940255 (c.1784_1802delinsGTCACA)

      gnomAD: N/A

    1. patient 2

      Case#: patient 2

      DiseaseAssertion: Glanzmann thrombasthenia

      **FamilyInfo: **

      ParentalGenotype: If noted by authors, annotate with the carrier status of each parent in regards to the variant(s) identified in the proband.

      CasePresentingHPOs:

      PlateletAggregation: absent platelet integrin αIIbβ3. Monolayer of spread platelets essentially devoid of fibrinogen binding but with high CD62P expression and phosphatidylserine exposure (Figure S1). Figure 5.

      CaseHPOFreeText:

      CaseNotHPOs:

      **CaseNotHPOFreeText: **

      ProteinExpression:

      CasePreviousTesting:

      **PreviouslyPublished: **

      Gene: ITGA2B

      **HGVS: **

      **ClinVar: **

      CAID:

      **gnomAD: **

      Gene: ITGA2B

      **HGVS: ** NM_000419.5:c.2051T>G

      **ClinVar: ** 1330350

      CAID: CA399799849

      **gnomAD: **

    1. Supplemental Table S1:

      Cases26-33: Males and Females from France, Spain and Italy and ages are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild to severe bleeding for probands

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 8-20% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European non finnish population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

      PreviouslyPublished: PMID: 9920835, 12083483, 12424194, 25728920, 20020534

    2. Supplemental Table S1:

      Case3: Male, USA, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe life threatening bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: >5% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1553T>A (p.Ile518Asn) and NM_000419.3:c.1946+3G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603038 and CA626121071

      gnomAD: MAF in the European (non-Finnish) population is 0.000008790 https://gnomad.broadinstitute.org/variant/17-42457661-A-T and MAF in the African population is 0.000 https://gnomad.broadinstitute.org/variant/17-42456008-C-A

      PreviouslyPublished: PMID: 25728920

    3. Supplemental Table S1:

      Case5: Male, India, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding from multiple sites

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 8% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045 https://gnomad.broadinstitute.org/variant/17-42457471-G-A

      PreviouslyPublished: PMID: 16879215

    1. GT-53

      Case43: (GT-53) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2113del (p.Leu705Cysfs*4)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623443

      gnomAD: MAF in East Asian population: 0.0001087 http://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    2. GT-45b

      Case35: (GT-45) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT45-GT48 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1879-2A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290949031

      gnomAD: N/A

    3. GT-29

      Case24: (GT-29) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT30 is related to GT29

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045 http://gnomad.broadinstitute.org/variant/17-42457471-G-A

    4. GT-04

      Case4: (GT-04) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands 1-9 are related to GT-04 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Mild (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 not observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1210+5G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940251

      gnomAD: N/A

    5. GT-07

      Case6: (GT-07) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands 1-9 are related to GT-07 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Mild (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 not observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1210+5G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940251

      gnomAD: N/A

    6. GT-02

      Case2: (GT-02) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands 1-9 are related to GT-02 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: N/A for proband 2 (See Supplemental Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 not observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1210+5G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940251

      gnomAD: N/A

    7. GT-43

      Case33: (GT-43) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT43-GT44 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Severe (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1620G>C (p.Gln540His) and NM_000419.3:c.1616T>G (p.Leu539Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802407 and CA399802416

      gnomAD: N/A

    8. GT-12

      Case10: (GT-12) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands GT11 -GT14 are related to GT-12 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: not available (See Supplemental Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.727G>C (p.Asp243His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023600

      gnomAD: N/A

    9. GT-62

      Case50: (GT-62) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Severe (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B and ITGB3

      Variant: NM_000419.3:c.985G>T (p.Val329Phe) and NM_000212.2:c.1265G>A (p.Ser422Asn)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804719 (p.Val329Phe) and CA291225740 (p.Ser422Asn)

      gnomAD: N/A

    1. Supplementary Table S1:

      Case48: GT55, Arg/Brazilian, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.647C>T (p.Ala216Val)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805506

      gnomAD: N/A

    2. Supplementary Table S1:

      Case49: GT57, Argentinian/European, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.571T>G (p.Phe191Ala/ p.Phe191AlafsTer32) and NM_000419.3:c.961G>T (p.Gly321Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805699 and CA399804768

      gnomAD: N/A

    3. Supplementary Table S1:

      Case30: GT35a, USA, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B and ITGB3

      Variant: ITGA2B: NM_000419.3:c.2264G>A (p.Arg755Gln) NM_000212.2:c.392G>C (p.Arg131Pro) and NM_000212.2:c.777+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602771, CA8622954, CA8623036

      gnomAD: MAF in the Latino population is 0.0001903 https://gnomad.broadinstitute.org/variant/17-42454380-C-T and MAF in the African population is 0.00006152 https://gnomad.broadinstitute.org/variant/17-45361839-G-C and MAF in the African population is 0.0006774 https://gnomad.broadinstitute.org/variant/17-45363789-G-A

    4. Supplementary Table S1:

      Case8: GT9, French, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.665T>C (p.Leu222Pro) and NM_000212.2:c.1871G>A (p.Cys624Tyr)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224887 and CA400032726

      gnomAD: MAF in the European (non-Finnish) population is 0.00006482 https://gnomad.broadinstitute.org/variant/17-45363676-T-C

    5. Supplementary Table S1:

      Case18: GT21, French, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1440-13_1440-1del (p.Arg480Serfs106) and NM_000419.3:c.2864T>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913184940 and CA399791171

      gnomAD: N/A

    6. Supplementary Table S1:

      Case29: GT34, USA, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1553T>A (p.Ile518Asn) and NM_000419.3:c.1946+3G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603038 and CA626121071

      gnomAD: MAF in the European (non-Finnish) population is 0.000008790 https://gnomad.broadinstitute.org/variant/17-42457661-A-T and MAF in the African population for NM_000419.3:c.1946+3G>T is 0.000 https://gnomad.broadinstitute.org/variant/17-42456008-C-A

    7. Supplementary Table S1:

      Case43: GT50, French, age and gender not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.1260G>A (p.Lys376_Thr420del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623200

      gnomAD: MAF in the African population is 0.00004005 https://gnomad.broadinstitute.org/variant/17-45368454-G-A

    8. Supplementary Table S1:

      Case21: GT24, French Gypsy, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A (p.Val513Leufs*71)

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    9. Supplementary Table S1:

      Case51: GT60, French/Italian, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.1801T>C (p.Cys601Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623361

      gnomAD: MAF in the European (non-Finnish) population is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    10. Supplementary Table S1:

      Case53: GT62, French, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.31T>C (p.Trp11Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291240306

      gnomAD: N/A

    1. GT7

      Case#: half a year old, male

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0000967, HP:0000978, HP:0002239

      PlateletAgreggation: Defective response to ADP, Adrenaline, Collagen, Arachidonic acid. Normal response to Ristocetin.

      GenotypingMethod: Genomic DNA was extracted from peripheral blood leukocytes for mutational analysis of the αIIb and β3 genes by DNA sequencing

      Allele 1:

      ClinVar: 996164

      CAID: CA400023596

      Variant: NM_000212.3:c.724C>T

      GnomAD: Highest in European (Non-Finnish) 0.00006483 (1/15426)

      Allele 2

      ClinVar: Not found

      CAID: CA626684825

      Variant: NM_000212.3:c.225_226del

      GnomAD: East Asian highest at rate of 0.0001087 2/18394

      ExpressionEvidence: Flow Cytometry of platelet integrin: .3% B3 expression, .6% A2B expression

    2. GT12

      Case#: 7 year old, female

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0000967, HP:0000978, HP:0000225, HP:0004406, HP:0006298, HP:0001892

      PlateletAgreggation: Defective response to ADP, Adrenaline, Collagen, Arachidonic acid. Normal response to Ristocetin.

      GenotypingMethod: Genomic DNA was extracted from peripheral blood leukocytes for mutational analysis of the αIIb and β3 genes by DNA sequencing

      Allele 1:

      ClinVar: 2892

      CAID: CA115834

      Variant: NM_000419.5:c.1750C>T

      GnomAD: East Asian Population 0.0002176 (4/18386)

      Allele 2:

      ClinVar: 225393

      CAID: CA290947544

      Variant: NM_000419.5:c.2333A>C

      GnomAD: East Asian at a rate of 0.0001087 (2/18394)

      ExpressionEvidence:Flow Cytometry of platelet integrin: 94.9% B3 expression, 5.66% A2B expression

    3. GT15

      Case#: 6 year old, male

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0000967, HP:0000978, HP:0004406, HP:0000225, HP:0006298, HP:0001892, HP:0002239

      PlateletAgreggation: Defective response to ADP, Adrenaline, Collagen, Arachidonic acid. Normal response to Ristocetin.

      GenotypingMethod: Genomic DNA was extracted from peripheral blood leukocytes for mutational analysis of the αIIb and β3 genes by DNA sequencing

      Allele 1:

      ClinVar: 2892

      CAID: CA115834

      Variant: NM_000419.5:c.1750C>T

      GnomAD: East Asian Population 0.0002176 (4/18386)

      Allele 2:

      ClinVar: 953046

      CAID: CA399802348

      Variant: NM_000419.5:c.1651C>T

      GnomAD: Highest in East Asian population at a rate of 0.00005045 (1/19820)

      ExpressionEvidence:Flow Cytometry of platelet integrin: 99.2% B3 expression, 3% A2B expression

    1. GT 03

      Case14: GT03, Female, India, age of onset is 6 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.166-14C>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622881

      gnomAD: MAF in the South Asian population is 0.00003274 https://gnomad.broadinstitute.org/variant/17-45360706-C-A

    2. GT 06

      Case2: GT06, Female, India, age of onset is 13 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.245dup (p.Gly83ArgfsTer19)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940723

      gnomAD: N/A

    3. GT 42

      Case30: GT42, Female, India, age of onset is 26 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.356G>A (p.Arg119Gln)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622925

      gnomAD: MAF in the African population is 0.0002470 https://gnomad.broadinstitute.org/variant/17-45360910-G-A

    4. GT 21

      Case23: GT21, Male, India, age of onset is 33 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.921C>A (p.Tyr307Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400025209

      gnomAD: N/A

    5. GT 60-1

      Case35: GT60-1, Female, India, age of onset is 27 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp)

      LegacyVariant: N/A

      ClinVar: 13567

      CAiD: CA123252

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G

    6. GT 11

      Case19: GT11, Female, India, age of onset is 12 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.115T>G (p.Cys39Gly)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400031666

      gnomAD: N/A

    1. Nonsense-mediated mRNA decay efficiency influencesbleeding severity inITGA2Bc.2659C > T (p.Q887X)knock-in mice

      PMID: 33928629

      Previously annotated and reported Probands: PMID: 29675921. New Functional Evidence.

      CAID: CA8602626

      Gene: ITGA2B

      Variant: NM_000419.3:c.2671C>T (p.Gln891Ter)

      FunctionalEvidence: For Q887X mutation: Knock-in mice generated using CRISPR/Cas9 displaed no spontaneous bleeding phenotypes. Platelet morphology cofirmed to be normal and comparable platelet numbers to WT mice. Mean bleeding time increased and platelet aggregation impaired compared to WT. ITGA2B mRNA levels low in KI mice.

    1. The propositus

      Case1: Female, age and ethnicity is previously described in Ruan et al, 1993, but access not available to this article

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: The propositus' twin brother was also affected

      ParentalGenotype: Article mentions, "Thus the two affected members are double heterozygote having inherited two different abnormal GPIIb alleles, one from the father and the other from the mother"

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding time > 15 minutes

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Absent or reduced platelet GPIIb and GPIIIa assessed by Western blotting

      PlateletAggregation: Absent platelet aggregation in response to ADP, epinephrine, and collagen and normal aggregation in response to ristocetin

      CasePreviousTesting: PCR was used to amplify the defective segment of the GPIIb gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: c.9644C>T

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    1. M9

      Case9: Patient M9, Male, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    1. Case14: Patient LRI, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Arg674Arg)

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

    2. Case6: Patient FF, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.855dup

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940766

      gnomAD: N/A

    3. Case18: Patient ME, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2929C>T (p.Arg977Ter)

      LegacyVariant: (p.Arg946Ter)

      ClinVar: N/A

      CAiD: CA8602528

      gnomAD: MAF in the South Asian population is 0.00003266 https://gnomad.broadinstitute.org/variant/17-42452041-G-A

    4. Case2: Patient PF, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.416C>T (p.Ala139Val)

      LegacyVariant: (p.Ala108Val)

      ClinVar: N/A

      CAiD: CA399806036

      gnomAD: N/A

    5. Case13: Patient BM, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Arg674Arg)

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

    6. Case19: Patient SM, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGB3

      Variant: NM_000212.2:c.355C>T and NM_000212.2:c.1801T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622924 and CA8623361

      gnomAD: MAF in the South Asian population is 0.0001307 https://gnomad.broadinstitute.org/variant/17-45360909-C-T and MAF in the European non Finnish pop is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    1. The proband was a 27-year old Danish woman

      Case1: Female, 27 years old, Danish

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Information on father, mother, brother and sister. (See Figure 1 for pedigree)

      ParentalGenotype: Pedigree from Figure 1 shows Father to have (p.Asn331Ser) and mother has (p.Arg786Trp) variant.

      CasePresentingHPOs: HP:0000978, HP:0001934, HP:0006298

      (Bruising, prolonged bleeding after minor trauma, prolonged bleeding after dental extraction)

      CaseHPOFreeText: Lifelong bleeding history

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: αIIbβ3 expression and activation and αvβ3 expression were assessed by flow cytometry (See Figure 1 and 2 for results)

      PlateletAggregation: Platelet aggregation was impaired in response to all stimuli except ristocetin, with low-normal response to collagen

      CasePreviousTesting: To identify DNA variants, all exons of ITGA2B and ITGB3 were analyzed by Sanger sequencing

      Gene: ITGB3

      Variant: NM_000212.2:c.2356C>T (p.Arg786Trp) an NM_000212.2:c.992A>G (p.Asn331Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400034866 (p.Arg786Trp) and CA400025729 (p.Asn331Ser)

      gnomAD: MAF for (p.Arg786Trp) in the African population is 0.000 https://gnomad.broadinstitute.org/variant/17-45387559-C-T

    1. The patient is a 2-year-old female from China

      Case1: Female, 3 years old, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A (No information about the family was available since the child was adopted)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Mucocutaneous hemorrhages, prolonged bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Protein expression was estimated by flow cytometry and western blot analysis. The analysis revealed less than 10% of surface expression of alphaIIbbeta3 relative to control platelets. (See Fig 2)

      PlateletAggregation: Platelet aggregation in response to ADP, collagen, adrenaline, and arachidonic acid was less than 5% that of control platelets, and no clot retraction was observed. Ristocetin-induced platelet agglutination and plasma fibrinogen content were within the normal range.

      CasePreviousTesting: Sequencing for mutations was carried out by direct sequencing of PCR overlapping fragments of reversed transcribed αIIb and β3 mRNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2829C>T (p.Pro943Leu), NM_000419.3:c.2621T>G (p.Ile874Ser), NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: (p.Ile843Ser) and (p.Arg553Ter) and (p.Pro912Leu)

      ClinVar: 2891, 2892

      CAiD: CA500263536, CA115831, CA115834

      gnomAD: MAF in the European (Finnish) population is 0.4395 https://gnomad.broadinstitute.org/variant/17-42453065-A-C and MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    1. 16CabGT-16

      Case16: (Proband CabGT-16), Male, age not specified, North African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed 2% GPIIb and 10% GPIIIa surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.2870C>T (p.Ser957Leu)

      LegacyVariant: N/A

      ClinVar: 2902

      CAiD: CA115850

      gnomAD N/A

    2. 14CabGT-14

      Case14: (Proband CabGT-14), Female, age not specified, North African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed <5% GPIIIa and GPIIb surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.2748_2757del (p.T917Sfs181)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290946532

      gnomAD MAF in the African population is 0.0001150 https://gnomad.broadinstitute.org/variant/17-42452449-GCACCACAGTA-G

    3. 22CabGT-22

      Case22: (Proband CabGT-22), Female, age not specified, South American

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression:

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGB3

      Variant: NM_000212.2:c.431T>G (p.Met144Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224645

      gnomAD N/A

    4. 10

      Case10: (Proband CabGT-10) Female, age not specifie,d North African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed <5% GPIIIa and GPIIb surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C (p.Gln626His)

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD N/A

    5. 19CabGT-19

      Case19: (Proband CabGT-19), Gender, age and ethnicity is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: N/A

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGB3

      Variant: NM_000212.2:c.166-2A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224483

      gnomAD N/A

    6. 26CabGT-26

      Case26: (Proband CabGT-26), Female, age not specified, North American

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed 12% of both GPIIIa and GPIIb surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGB3

      Variant: "c.1143C>A" is incorrect in the CAR- so will need a senior biocurator to ask-- and NM_000212.2:c.1260G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623200

      gnomAD MA in the African population is 0.00004005 https://gnomad.broadinstitute.org/variant/17-45368454-G-A

    1. Case 6

      Case#: 18 yo, Male (deceased)

      DiseaseAssertion: GT

      FamilyInfo: Uncle diagnosed GT, 2 siblings diagnosed GT. No pedigree. Experienced mild episodes of bleeding (gum bleeding, bruises, ecchymosis).

      CasePresentingHPOs: (HP:0002249) Melena; (HP:0002573) Hematochezia

      PlateletAggregation: Prothrombin time: 12.2, Partial thromboplastin time: 31.4, Platelet function analyzer-100: 235

      CaseHPOFreeText: Hemoglobin (Hb) level was 10.8 upon admission, dropped to 5.3

      ProteinExpression: Flow cytometry: CD41 and 61 absent

      CasePreviousTesting: Molecular sequencing, Patients’ information was obtained from the medical record system of the Madinah Hereditary Blood Disorders Center, Maternity and Children Hospital, King Fahd Hospital, Al Madinah, Saudi Arabia.

      Gene: ITGA2B

      HGVS: NM_000419.5(ITGA2B):c.1210+5G>A

      ClinVar: 1210188

      CAID: CA915940251

      gnomAD: 0 https://gnomad.broadinstitute.org/variant/chr17-44383488-C-T?dataset=gnomad_r4

    1. 4

      Case4: Female, 35 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A per Table 1

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Prolonged ivy bleeding times, bleeding diathesis since early childhood

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 was analyzed by flow cytometry which was 10-20% of normal

      PlateletAggregation: Aggregation in response to ADP, epinephrine and collagen was absent but normal in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of the αIIb and β3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro)

      LegacyVariant: (p.Gln747Pro)

      ClinVar: 225393

      CAiD: CA290947544

      gnomAD: MAF in the East Asian population is 0.0001087 https://gnomad.broadinstitute.org/variant/17-42453691-T-G

    2. cases 3

      Case3: Female, 32 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A per Table 1

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Prolonged ivy bleeding times, bleeding diathesis since early childhood

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 was analyzed by flow cytometry which was 10-20% of normal

      PlateletAggregation: Aggregation in response to ADP, epinephrine and collagen was absent but normal in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of the αIIb and β3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro)

      LegacyVariant: (p.Gln747Pro)

      ClinVar: 225393

      CAiD: CA290947544

      gnomAD: MAF in the East Asian population is 0.0001087 https://gnomad.broadinstitute.org/variant/17-42453691-T-G

    1. M4

      Case12: (M4) Female, 17 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    2. M10

      Case18: (M10) Female, 37, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    1. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia.

      Case1: Female, 20 years old, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents were heterozygous for mutation (See Fig 3)

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000967, HP:0000979, HP:0000132

      (Epistaxis, gingival bleeding, petechiae, purpura, severe menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Surface GPIIb/IIIa expression was < 15% of normal

      Platelet Aggregation: Absent platelet aggregation in response to ADP, epinephrine, or collagen but normal response to ristocetin

      CasePreviousTesting: Direct sequencing of PCR amplified cDNA and GPIIIa exon VIII indicated that the patient was homozygous for the mutation

      Gene: ITGB3

      Variant: NM_000212.2:c.1199G>A (p.Cys400Tyr)

      LegacyVariant: (p.Cys374Tyr)

      ClinVar: 13562

      CAiD: CA123244

      gnomAD N/A

    1. M/22

      Case4: Male, 22 years old, Tamil Nadu India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0006298, HP:0000421, HP:0002239, HP:0000225

      (Prolonged bleeding after tooth extraction, epistaxis, GI bleeding, gingival bleeding)

      CaseHPOFreeText: Bleeding during tooth extraction

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1162G>A (p.Gly388Ser)

      LegacyVariant: (p.Gly357Ser)

      ClinVar: N/A

      CAiD: CA8603212

      gnomAD: N/A

    2. M/20

      Case9: Male, 20 years old, Tamil Nadu India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000225, HP:0006298

      (Epistaxis, ecchymosis, gingival bleeding, prolonged bleeding after dental extraction)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.2489T>G (p.Leu830Arg)

      LegacyVariant: (p.Leu799Arg)

      ClinVar: N/A

      CAiD: CA8602667

      gnomAD: MAF in the South Asian population is 0.00003270 https://gnomad.broadinstitute.org/variant/17-42453313-A-C

    3. M/11

      Case7: Male, 1 years old, West Bengal India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0006298, HP:0000967

      (Gingival bleeding, prolonged bleeding after tooth extraction, petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: (p.Arg520Trp)

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045https://gnomad.broadinstitute.org/variant/17-42457471-G-A

    1. GT70

      Case25: (GT70) Gender, age, and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2673_2674dup and NM_000419.3:c.1424_1427dup

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940687 and CA8603099

      gnomAD MAF in the South Asian population is 0.0001960 https://gnomad.broadinstitute.org/variant/17-42457979-C-CACCT

    2. GT30

      Case28: (GT30) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother and father are heterozygous for the mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.674del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940689

      gnomAD N/A

    3. GT10

      Case20: (GT10)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.59T>C (p.Leu20Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400028389

      gnomAD N/A

    4. GT72

      Case17: (GT72) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.1641C>G (p.Cys547Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400030171

      gnomAD N/A

    5. 58

      Case9: (GT58), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1028T>C (p.Leu343Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804619 (p.Leu343Pro)

      gnomAD N/A

    6. 69

      Case4: (GT69), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NC_000017.11:g.44393555C>T (g.951G>A promoter variant) and NM_000419.3:c.1028T>C (p.Leu343Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189168 (promoter variant) and CA399804619 (p.Leu343Pro)

      gnomAD N/A

    7. 67

      Case23: (GT67) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene:

      Variant: NM_000419.3:c.1919_1920del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940685

      gnomAD N/A

    1. one of the patient affected

      Case1: Gender, age, and ethnicity not reported here

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.800G>A (p.Gln267Glu)

      LegacyVariant: (p.Gln236Glu)

      ClinVar: N/A

      CAiD: CA399805147

      gnomAD: N/A

      PreviouslyPublished: PMID: 12083483 (Access not available to this article)

    1. A 66-year-old male

      Case1: Male, 66 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Information of proband's child in Figure 2

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0011890

      (Prolonged bleeding following procedure)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: On admission to the hospital, proband had no sign or symptoms of bleeding.

      ProteinExpression: In comparison to normal platelets, very low αIIbβ3 (1,053 ± 544 copies/platelet, n=3) and αvβ3 (755 ± 180 copies/platelet, n=3) expression were measured on the cell surface expression of our patient’s platelets.

      PlateletAggregation: Light transmission aggregometry showed his platelets were unable to respond to ADP, collagen, arachidonic acid, and epinephrine; however, platelet agglutination in response to ristocetin was normal.

      CasePreviousTesting: To identify the molecular genetic defect in this patient, we isolated genomic DNA from the patient’s leukocytes and amplified all exons of ITGA2B and ITGB3 gene by PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.1697G>A (p.Gly566Asp)

      LegacyVariant: (p.Gly540Asp)

      ClinVar: N/A

      CAiD: CA400032338

      gnomAD: N/A

    1. 2

      Case2: Female, Iraq, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for the proband, however no specific details about family provided in paper

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132, HP:0002249

      (Epistaxis, gingival bleeding, menorrhagia, melena)

      CaseHPOFreeText: Petechial rash, post-partum bleeding, colon angiodysplasia, haematemesis

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.2031_2041del (p.Asp677Glufs)

      LegacyVariant: (p.Asp651Glufs*3)

      ClinVar: N/A

      CAiD: CA915940605

      gnomAD: N/A

    2. 9

      Case9: Male, Iraq, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0031364, HP:0030137, HP:0002573

      (Epistaxis, gingival bleeding, ecchymosis, prolonged bleeding following circumcision, rectal bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.2031_2041del (p.Asp677Glufs)

      LegacyVariant: (p.Asp651Glufs*3)

      ClinVar: N/A

      CAiD: CA915940605

      gnomAD: N/A

    1. Patient 1

      Case1: Male, 2 years old, Korean

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Figure 1 shows haplotype analysis

      CasePresentingHPOs: HP:0000978, HP:0000967

      (Easy bruising, petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analyses revealed markedly decreasedCD41/CD61 expression (<1%) in Patient 1 (type I GT).

      PlateletAggregation: Platelet aggregation tests were performed to evaluate responses to ADP, collagen, epinephrine, and ristocetin agonists

      CasePreviousTesting: Polymerase chain reaction for all exons ofITGA2Band/orITGB3were performed using primers. Sequence analysis was performed with reference to M_000419.3 andNP_000410.2 forITGA2Band NM_000212.2 and NP_000203.2 for ITGB3.

      Gene: ITGB3

      Variant: NM_000212.2:c.1913+5G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623377

      gnomAD: MAF in the East Asian population is 0.0001633 http://gnomad.broadinstitute.org/variant/17-45376901-G-T

    2. Patient 2

      Case2: Male, 38 years old, Korean

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Figure 1 shows haplotype analysis

      CasePresentingHPOs: HP:0004406, HP:0000225

      (Recurrent epistaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analyses revealed markedly decreasedCD41/CD61 expression (<1%) in Patient 2 (type I GT).

      PlateletAggregation: Platelet aggregation tests were performed to evaluate responses to ADP, collagen, epinephrine, and ristocetin agonists

      CasePreviousTesting: Polymerase chain reaction for all exons ofITGA2Band/orITGB3were performed using primers. Sequence analysis was performed with reference to M_000419.3 andNP_000410.2 forITGA2Band NM_000212.2 and NP_000203.2 for ITGB3.

      Gene: ITGB3

      Variant: NM_000212.2:c.1913+5G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623377

      gnomAD: MAF in the East Asian population is 0.0001633 http://gnomad.broadinstitute.org/variant/17-45376901-G-T

    1. F1.III.4

      Case#: 26 year old female

      Disease: Glazmann's Thrombasthenia Like Syndrome

      CasePresentingHPOs: HP:0000978, HP:0001873

      Bruising susceptibility, Thrombocytopenia,

      CaseNotHPOs: HP:0004846

      FamilyInfo: Three sisters all with thrombocytopenia and easy bruising/nose bleeding during infancy. Mother and grandmother had identical phenotype. Disease segregation with thrombocytopenia and decreased GPIIb/IIIa in the affected patients was confirmed. Pedigree figure 1.

      PlateletAgreggation: Famiy member studied: Decreased PLT aggregation and diminished ATP release with the agonists ADP, collagen, and AA, Ristocetin not assessed in individual per supplementary table.

      GenotypingMethod: genetic analysis of ITGA2B and ITGB3 genes was performed by next-generation sequencing (NGS). Sanger sequencing used to confirm variants.

      ClinVar: 50233

      CAID: CA10575573

      Variant: NM_000419.5:c.3076C>T

      GnomAD: Not Found

      ExpressionEvidence: Level of expression on PLT surface determined by FCM: CD41a (GPIIb/IIIa) 45%, CD61 (GPIIIa) 56%, and CD42b (GPIb) 155%. Healthy control value range: CD41a (GPIIb/IIIa) (85-115%); CD61 (GPIIIa) (80-120%); CD42b (GPIb) (70-130%).

    1. HS

      Case6: Patient HS, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD: N/A

    2. GE

      Case8: Patient GE, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.2051T>G (p.Leu684Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399799849

      gnomAD: N/A

    3. LB

      Case18: Patient LB, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Child is patient LN, significant other is patient LH

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.3062T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399787956

      gnomAD: N/A

    4. TN

      Case14: Patient TN, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.3060G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500261104

      gnomAD: N/A

    1. A 30year old primigravida type-I GT patient

      Case1: 30 year old, Female (primigravada), ethnicity not reported

      DiseaseAssertion: Type-1 Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: See Table 1 (Father wild type and mother has frameshift mutation)

      CasePresentingHPOs: HP:0000132 (Menorrhagia)

      CaseHPOFreeText: Vaginal bleeding, haematochezia

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: Proband did not have any bleeding manifestations at the age of 16

      ProteinExpression: Using flow cytometry, the test sample (normal plate-lets+patient plasma) showed only 28% GPIIb-IIIa expression as compared to 81.4% GPIIb-IIIa expression seen in the control sample(normal platelets+control plasma) (Fig. 1B) confirming the presence of GPIIbIIIa antibodies in patient plasma.

      PlateletAggregation: Absent aggregation in response to ADP and collagen and normal response to ristocetin (Platelet aggregation information found in Table 1)

      CasePreviousTesting: The mutation analysis was performed by Sanger sequencing of both ITGA2B and ITGB3 genes, which showed a frameshift mutation: c.1230_1230delC, cDNA.1262_1262delC (Y411Tfs*20) due to a single base deletion in exon 13 of ITGA2B

      Gene: ITGA2B

      Variant: NM_000419.3:c.1230del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940214

      gnomAD: N/A

    1. GT1

      Disease: Glazmann's Thrombasthenia

      Case: 11 year old female French Gypsy

      CasePresentingHPOs: HP:0001975

      (Decreased platelet glycoprotein IIb-IIIa)

      GenotypingMethod:Genotyping analysis of the HPA-1 system by high resolution melting analysis (methods not provided, cited article I don't have access too)

      ClinVar: 2895

      CAID: CA10575473

      Variant: NM_000419.5:c.1544+1G>A

      GnomAD: Not found

      ExpressionEvidence: Failed to express αIIbβ3 integrin on their platelet surface (methods not provided cited article no access too)

    1. 3/M

      Case#: Patient ID 6, Male 3 years old. North Indian

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0003540, HP:0000967, HP:0002239

      Impaired platelet aggregation, Petechiae, Gastrointestinal hemorrhage

      PlateletAgreggation: LTA with ADP, Epi, Coll, AA, and Ristocetin: Impaired with all agonists

      GenotypingMethod: Next generation sequencing. Sanger sequencing used to confirm pathogenic variants

      ClinVar:1691486

      CAID: CA399794330

      Variant: NM_000419.5:c.2578C>T

      GnomAD: NA

      ExpressionEvidence:Flow Cytometry for platelet expression of GPIIb/IIIa in CD41a 0% and CD61 0%.

    1. The patient, a 33-mo-old boy

      Case1: Male, 33 months old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother heterozygous for the c.1544+1G>A variant

      CasePresentingHPOs: HP:0000967, HP:0000979, HP:0002094

      (Petechiae, purpura, dyspnea,

      CaseHPOFreeText: Hypoxia

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis showed GPIIb/IIIa expression to be 22.6.

      PlateletAggregation: Platelets failed to aggregate in response to ADP, epinephrine, collagen, calcium ionophore, and TRAP; however, ristocetin-induced aggregation was normal

      CasePreviousTesting: Sequencing of coding regions of ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    1. male patient

      Case1: Male, French, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Son was heterozygous carriers of the p.Leu196Pro mutation (Sister died from nasal bleeding when she was a child)

      ParentalGenotype: Mother is heterozygous for p.Leu196Pro mutation (Father not alive)

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Lifelong history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Expression showed 8% of normal platelet content for αIIbβ3

      PlateletAggregation: Absent aggregation to physiologic agonists

      CasePreviousTesting: Screened exons and splice sites of ITGB3 and ITGA2B genes of patient by single-strand conformation polymorphism analysis of PCR products.

      Gene: ITGB3

      Variant: NM_000212.2:c.665T>C (Leu222Pro) and NM_000212.2:c.1871G>A (p.Cys624Tyr)

      LegacyVariant: p.Leu196Pro and p.Cys598Tyr

      ClinVar: N/A

      CAiD: CA291224887 and CA400032726

      gnomAD: N/A

    1. The propositus is a 49 year-old French woman

      Case1: Female, 49 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia (diagnosed when 5 years old)

      FamilyInfo: A brother died from hemorrhage when he was 4 years old, but an adult sister has never experienced untoward bleeding. (Case History Supp Table 1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0004406, HP:0000132, HP:0000225, HP:0000790

      (Easy bruising, recurrent epistaxis, menorrhagia, gingival bleeding, hematuria

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis showed no biding of P2 and AP-2, two MoAbs recognizing alphaIIbBeta3 and a very weak binding of MoAbs to Beta3 to platelets of the proband

      PlateletAggregation: Platelet function testing confirmed an absence of aggregation to ADP, collagen, arachidonic acid and thrombin but the response to ristocetin was normal (Case History Supp Table 1)

      CasePreviousTesting: Direct sequencing of all exons and splice sites of ITGA2B (30 exons) and ITGB3 (15 exons) was performed by the French National Sequencing Center. Briefly, exons and flanking regions of ITGA2B and ITGB3 were amplified by PCR with a high fidelity Taq polymerase permitting large fragment amplification. PCR fragments were sequenced.

      Gene: ITGB3

      Variant: (p.Pro189Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224669

      gnomAD: MAF in European (non-Finnish) population is 0.00002638 http://gnomad.broadinstitute.org/variant/17-45362012-C-T

    1. An 18-year-old woman was found to have GT

      Case1: Female 18 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0025636 (Endometriosis)

      CaseHPOFreeText: "Endometriosis and bleeding"

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: See Table 1 (information provided)

      PlateletAggregation: N/A

      CasePreviousTesting: Sequenced GPIIIa by PCR

      Gene: ITGB3

      Variant: NM_000212.2:c.166-2A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224483

      gnomAD: N/A

    1. Table 3 Molecular Diagnosis of Patients with Glanzmann Thrombasthenia:

      Case2: GT-2, age, gender, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Segregation analysis confirmed in presence of heterozygous mutations in this proband.

      ParentalGenotype: Although segregation analysis confirmed, we do not know which variant in particular came from mom or dad.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients presented with a variable bleeding diathesis; most patients had epistaxis (54%), cutaneous bleeding (58%), and menorrhagia (100% of women) while other common symptoms (oral cavity, GI, following dental extraction of mild injuries, postpartum, or hematomas) were in general milder. There is no specific phenotypes attached to probands in this paper.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that αIIbβ3 expression was less than 5%

      PlateletAggregation: There was severely impaired aggregation in response to all physiological agonists, and ristocetin induced platelet agglutination was normal or reduced to some extent.

      CasePreviousTesting: Total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Then, using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing. Every mutation found in cDNA was confirmed in DNA samples.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2473_2481delinsTCACCTGGTC and NM_000419.3:c.641T>C (p.Leu214Pro)

      LegacyVariant: p.Leu183Pro

      ClinVar: (p.Leu214Pro is 2901)

      CAiD: CA915940289 and CA115848

      gnomAD: N/A

    1. 7

      Case7: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0005542, HP:0000132, HP:0000421, HP:0000978

      (Prolonged clotting, menorrhagia, epistaxis, easy bruising)

      CaseHPOFreeText: Bleeding time greater than 20 minutes

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1899del (p.Cys633TrpfsTer17)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940223

      gnomAD: N/A

    2. 4

      Case4: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0000978, HP:0000132, HP:0000421, HP:0000979

      (Easy bruising, menorrhagia, epistaxis, purpura)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.1303G>T (p.Glu435Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400028645

      gnomAD: N/A

    3. 13

      Case12: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1555C>T (p.Gln519Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802559

      gnomAD: N/A

    1. Patient Osaka-5

      Case1: (Osaka-5) Female, 33 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that the amount of αIIbβ3 expressed was about 6% of normal platelets

      PlateletAggregation: N/A

      CasePreviousTesting: Coding regions of ITGA2B and ITGB3 cDNAs were amplified by RT PCR

      Gene: ITGB3

      Variant: NM_000212.2:c.917A>C (p.His306Pro)

      LegacyVariant: (p.His280Pro)

      ClinVar: N/A

      CAiD: CA291224999

      gnomAD: https://gnomad.broadinstitute.org/variant/17-45364575-A-C

    1. 13

      Case13: Female, 9 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0002248, HP:0000421, HP:0031364 (Haematemesis, epistaxis, ecchymosis)

      CaseHPOFreeText:

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2674del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940582

      gnomAD: N/A

    2. 12

      Case12: Male, 3 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Sibling is proband number 11 in this article

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0002249, HP:0000421 (Melena, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1600+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802454

      gnomAD: N/A

    1. 3

      Case3: Gender or age not specified, Thai ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Parental information available in Table 2

      ParentalGenotype: Father: p.Arg782Ter/WT and Mother: Unavailable

      Note: No parental consanguinity

      CasePresentingHPOs: N/A

      CaseHPOFreeText: The article does not mention specific bleeding phenotypes for each of the 4 probands in the article, rather, there is a general statement that says: "The common presentations included recurrent epistaxis, bleeding in oral cavity, and easy-bruising spontaneously or after trauma"

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinEpression: General statement from the article that states that flow cytometry to assess the surface GPIIb/IIIa complex showed reduced expression for all probands.

      PlateletAggregation: The platelet aggregation test was typically defective with all physiological agonists except ristocetin, for all patients.

      CasePreviousTesting: Whole exome sequencing was performed on the 30 exons of ITGA2B and 15 exons in ITGB3. PCR and direct sequencing were then performed in the DNA samples of the patients and their available parents to verify the presence of the identified mutations.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2344C>T (p.Arg782Ter) and NM_000419.3:c.2915dup (p.Leu973Alafs*63)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399796586 (p.Arg782Ter) and CA8602531 (p.Leu973Alafs*63)

      gnomAD: MAF for (p.Leu973Alafs*63) in East Asian population 0.0001088 http://gnomad.broadinstitute.org/variant/17-42452054-C-CG

    2. 2

      Case2: Gender or age not specified, Thai ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Parental information available in Table 2

      ParentalGenotype: Father: p.Val206Asp/WT and Mother: also p.Val206Asp/WT (See Table 2)

      Note: Yes to parental consanguinity

      CasePresentingHPOs: N/A

      CaseHPOFreeText: The article does not mention specific bleeding phenotypes for each of the 4 probands in the article, rather, there is a general statement that says: "The common presentations included recurrent epistaxis, bleeding in oral cavity, and easy-bruising spontaneously or after trauma"

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinEpression: General statement from the article that states that flow cytometry to assess the surface GPIIb/IIIa complex showed reduced expression for all probands.

      PlateletAggregation: The platelet aggregation test was typically defective with all physiological agonists except ristocetin, for all patients.

      CasePreviousTesting: Whole exome sequencing was performed on the 30 exons of ITGA2B and 15 exons in ITGB3. PCR and direct sequencing were then performed in the DNA samples of the patients and their available parents to verify the presence of the identified mutations.

      Gene: ITGA2B

      Variant: NM_000419.3:c.617T>A (p.Val206Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805578

      gnomAD: N/A

    1. A rare case of Glanzmann's thrombasthenia and factor VII deficiency due to a combination of pathogenic and non-pathogenic gene variants

      PMID: 31777146

      Disease: Glazmann's Thrombasthenia type 1 and factor 7 deficiency

      Case: 13 year old male, from non-consanguineous

      CasePresentingHPOs: HP:0011889, HP:0000978, HP:0031364,

      GenotypingMethod: Direct sequencing of all coding, splice site and promoter regions of F7 and ITGA2B and ITGB3 genes. Heterozygous for two ITGB3 variants predicted to be deleterious in silico.

      First heterozygous mutation:

      ClinVar: Not found

      CAID: CA400022111

      Variant: NM_000212.3:c.473A>T

      GnomAD: Not found

      Second heterozygous mutation:

      ClinVar: Not found

      CAID: CA400033092

      Variant: NM_000212.3:c.2027A>C

      GnomAD: Not found

      PlateletAggregation: Platelet aggregation studies showed absent aggregation with adenosine diphosphate (ADP), collagen and was reduced with ristocetin

      ExpressionEvidence: flow cytometry studies for platelet receptors showed absence of αIIbβ3 integrin and normal levels of GPIb and GPIX receptors

  2. watermark.silverchair.com watermark.silverchair.com
    1. Recently, we reported the case of an 8-year-old boy with a variant form of GT

      Case1: Male, 8 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Sister had no bleeding tendency (all the information given in the previously published article cited in this annotation)

      ParentalGenotype: Parental mutations shown in Fig. 3 A and B

      CasePresentingHPOs: HP:0000421

      (Epistaxis)

      CaseHPOFreeText: Tonsilar bleeding

      CaseNotHPOs: HP:0000979

      (Purpura)

      CaseNotHPOFreeText: N/A

      ProteinExpression: Western blotting indicated that the proband's platelets contained no normal GPIIb, but showed a trace amount of an abnormal GPIIb (-6% with respect to the GPIIb level in a normal individual).

      PlateletAggregation: Decreased aggregation in response to ADP, collagen and epinephrine but a normal ristocetin-induced aggregation (this information was obtained from the previously published article cited at in this annotation)

      CasePreviousTesting: Genomic DNA fragments containing exons of the GPIIb gene were amplified by PCR

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter) and NM_000419.3:c.2602-3C>G

      LegacyVariant: N/A

      ClinVar: 2892 and 2893

      CAiD: CA115834 and CA10575472

      gnomAD: MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A and MAF in the East Asian population is 0.00006523 https://gnomad.broadinstitute.org/variant/17-42453087-G-C

      PreviouslyPublished: PMID: 1891767

    1. The proband

      Case#: Female, 29 yo

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Figure 2 Father and brother, unaffected carriers. Mother, unaffected negative. Sister, affected: Epistaxis, Cutaneous bleeding, Menorrhagia, Hematuria, Postpartum bleeding, Other bleeding symptoms (Ruptured corpus luteum bleeding)

      ParentalGenotype: Father carrier, unaffected. Mother negative, unaffected.

      CasePresentingHPOs: HP:0000421, Epistaxis. HP:0000132, Menorrhagia. HP:0000790, Hematuria. HP:0003540, Impaired platelet aggregation. HP:0001892, Abnormal bleeding. HP:0003010, Prolonged bleeding time. HP:0034263, Abnormal vaginal bleeding.

      PlateletAggregation: Normal platelet morphology, count 159 (125-350), MPV 10.6 fL (6.5-12.0), and PDW 12% (19-17). Decreased platelet aggregation: ADP 29.7& (30-70), Collagen 14.5% (30-70), AA 14.5% (40-80). Normal response to ristocetin, 88.7% (40-80). Thromboelastography (TEG) examination: hypocoagulable.

      CaseHPOFreeText: Cutaneous bleeding, Postpartum bleeding, Blood accumulation in the uterine cavity, Bleeding in ovaries, Vaginal bleeding during pregnancy,

      CaseNotHPOs: HP:0011875, Abnormal platelet morphology. HP:0011873, Abnormal platelet count.

      ProteinExpression: Protein structure model: destroyed local beta folding structure and molecular changes to structure of GPII beta helical region reduces the expression of GP IIb/IIIa. Proband refused further testing (flow cytometry).

      Gene: ITGA2B

      Variant: c.2822G>A, p. (Trp941Ter)

      HGVS: NM_000419.5:c.2822G>A

      ClinVar: absent

      CAID: CA399791662

      gnomAD: 0.00 https://gnomad.broadinstitute.org/variant/chr17-44375017-C-T?dataset=gnomad_r4

    1. F5P1

      Case1: Patient F1P1, Male, 11 years old, Tunisian

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Table 1 states there is a family history of bleeding (we have minimal to no specific info on this)

      ParentalGenotype: Mother and father are heterozygous for mutation

      CasePresentingHPOs:

      CaseHPOFreeText:

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: GT diagnosis was based on absent platelet aggregation induced by ADP, collagen, and TRAP and subnormal or cyclical ristocetin induced agglutination

      CasePreviousTesting: Using PCR they successfully amplified 20 DNA fragments for the ITGA2B gene (covering more than 48% of the ITGA2B gene constituting 30 exons) and15 DNA fragments of theITGB3gene (covering 15 exons)

      Gene: ITGA2B

      Variant: NM_000419.3:c.2702C>A (p.Ser901X) another variant this patient has is g.13944G>A --> I am noting this as Unknown Variant as I will need guidance curating this one

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399792888

      gnomAD: N/A

    2. F2P1

      Case2: Patient F2P1, Male, 34 years old, Tunisian

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Table 1 states there is a family history of bleeding (we have minimal to no specific info on this)

      ParentalGenotype: Mother and father are heterozygotes for the mutation here

      CasePresentingHPOs, : HP:0000225, HP:0004406, HP:0000978,HP:0000790

      (Gingival bleeding, recurrent epistaxis, easy bruising, hematuria)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: GT diagnosis was based on absent platelet aggregation induced by ADP, collagen, and TRAP and subnormal or cyclical ristocetin induced agglutination

      CasePreviousTesting: Using PCR they successfully amplified 20 DNA fragments for the ITGA2B gene (covering more than 48% of the ITGA2B gene constituting 30 exons) and15 DNA fragments of theITGB3gene (covering 15 exons)

      Gene: ITGA2B

      Variant: NM_000419.3:c.2702C>A (p.Ser901X) another variant this patient has is g.13944G>A --> I am noting this as Unknown Variant as I will need guidance curating this one

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399792888

      gnomAD: N/A

    1. A Glanzmann patient, LeM

      Case2: Patient LeM

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Platelets lack surface αIIbβ3 expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1366_1371del V(425)D(426)del and other other variant is stated as "Unknown" in the GT database. See GT database if questions arise, this is where I found the variants

      LegacyVariant: N/A

      ClinVar: 2898

      CAiD: CA8603160

      gnomAD: MAF in the European (non-Finnish) population is 0.000008791 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000419.3%3Ac.1366_1371del

  3. watermark.silverchair.com watermark.silverchair.com
    1. Patient MK

      Case1: (Patient MK), Female, Pakistani, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000967, HP:0000979

      (Petechiae, purpura)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Figure 1 shows protein expression by flow cytometry

      PlateletAggregation: Absence of platelet aggregation in response to ADP, epinephrine, and collagen but a normal response to ristocetin

      CasePreviousTesting: Genomic DNA containing all of the exons of the aIIb and b3 genes and 500 bp of DNA immediately upstream of each transcriptional start site was isolated from the patient and normal controls. Screening for mutations was performed by using single stranded conformation polymorphism analysis. PCR amplification was performed as well.

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp)

      LegacyVariant: (p.Leu117Trp)

      ClinVar: 13567

      CAiD: CA123252

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G

    1. Patient 1

      Case1: Male, 14 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: Sister is also heterozygous for this mutation but shows no bleeding symptoms

      ParentalGenotype: Both parents are heterozygous for this mutation

      Note: There is parental consanguinity

      CasePresentingHPOs: HP:0000967, HP:0000225, HP:0000421

      (Petechiae, ginigival bleeding, epistaxis)

      CaseHPOFreeText: Haematoma,

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis revealed 3.8 % platelet surface presentation of the αIIbβ3 complex for patient 1 and αIIb was not detected and β3 was significantly reduced in Western blots. Platelets from GT patients showed less than 5 % relative levels of the integrin subunit IIb and 5–9 % fibrinogen compared to controls.

      PlateletAggregation: Article states agonist-induced platelet aggregation and binding of exogenous fibrinogen was pathological, too but does not mention specific agonists used or response to ristocetin

      CasePreviousTesting: Molecular genetic analysis was done; however, no other information mentioned. In addition, the global proteome of highlight purified washed platelets was quantified by liquid chromatography-mass spectrometry and targeted MS-methods.

      Gene: ITGA2B

      Variant: NM_000419.3:c.175del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940266

      gnomAD: N/A

    1. 3

      Patient3: Female, 4.5yo, Family B (fig. 2)

      CasePresentingHPOs: HP:0001733 (pancreatitis)

      HPOsFreeText: acute neonatal IVA, treated with IVA special formula and vegetarian diet, stopped formula at 2yo and remained on vegetarian diet. Urinary organic acid analysis showed elevated lactic acid, 3-hydroxy-isovaleric acid, and isovalerylglycine, C5-carnitine = 10.8 µmol/l, fluctuating levels of serum ammonia which were eventually normalized with oral sodium benzoate treatment, admitted to hospital 2 times for gastroenteritis with metabolic acidosis and then for recurrent vomiting due to acute pancreatitis. sat unsupported at 6mo, walked and spoke first word at 12mo. As last physical, height = 105cm, weight = 18kg, and had unremarkable neurologic, chest, cardiovascular, and abdominal exams

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: diagnosed at birth via NBS, consanguineous family

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: c.ins386T (p.Tyr129fs) no ClinVar or CAID

      Variant2: NM_002225.3(IVD):c.732C>T (p.Asp244=)

      ClinVar: 94057, https://www.ncbi.nlm.nih.gov/clinvar/variation/94057/

      gnomAD: n/a

      Variant3: NC_000015.9:g.40699940T>C (NM_002225.4(IVD):c.234+14C=)

      CAID: CA147572, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NC_000015.9%3Ag.40699940T%3EC

      ClinVar: 94053, https://www.ncbi.nlm.nih.gov/clinvar/variation/94053/

      gnomAD: 0.6830, https://gnomad.broadinstitute.org/variant/15-40699940-T-C

    2. 8

      Patient8: Male, 6yo, Family C (fig. 2)

      CasePresentingHPOs: HP:0000486, HP:0000651 (squint, diplopia)

      HPOsFreeText: acute neonatal IVA, treated with IVA special formula and oral L-carnitine, elevated isovalerylglycine, C5-carnitine = 6.8 µmol/l, normal development for age, weight = 128cm, weight = 28kg, normal chest, cardiovascular, and abdominal exams

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: diagnosed at 3do via NBS, consanguineous family, family history and multiple sibling deaths

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_002225.3:c.1207T>A

      CAID: CA391724509, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA391724509

      gnomAD: n/a

      Variant2: NC_000015.9:g.40699940T>C (NM_002225.4(IVD):c.234+14C=)

      CAID: CA147572, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NC_000015.9%3Ag.40699940T%3EC

      ClinVar: 94053, https://www.ncbi.nlm.nih.gov/clinvar/variation/94053/

      gnomAD: 0.6830, https://gnomad.broadinstitute.org/variant/15-40699940-T-C

    1. 32

      Case32 Male, 13.6yo report, Ethnicity: Turkish

      CasePresentingHPOs HP:0003571, HP:0001531, HP:0008947, HP:0002789, HP:0001259, HP:0002045, HP:0002240

      (proprionicacidemia, failure to thrive in infancy, infantile hypotonia, tachypnea, coma, hypothermia, hepatomegaly)

      HPOsFreeText feeding difficulties, failure to thrive, hypotonia, tachypnea, coma, hypothermia, hepatomegaly(4do). 57 IQ on Snijders-Omen Test

      CaseNotHPOs n/a

      CasePreviousTesting Diagnosed by newborn screening. Patient fibroblasts had 0.7% PCC activity of controls.

      Variant NM_000532.4:c.613G>T (p.Val205Phe), homozygous

      ClinVar n/a

      CAID CA354641901

      gnomAD not in gnomAD

      CaseAddInfo parental consanguinity

      CasePMIDs n/a

    2. sib of 30

      FamilyLabel 29/30 Fam

      Family29/30PresentingHPOs HP:0003571, HP:0002789

      (Propionicacidemia, Tachypnea)

      HPOsFreeText n/a

      FamilyNotHPOs n/a

      CountryOrigin n/a

      Ethnicity Iraqi

      Race n/a

      Family29/30PreviousTesting n/a

      ProbandLabel 29

      Variant NM_000532.4:c.183+2T>C (p.=), homozygous

      ClinVar n/a

      CAID CA354738149

      gnomAD not in gnomAD

      FamilyAddInfo parental consanguinity

      FamilyPMIDs n/a

    3. 23

      Case23 Female, 5.2yo report, Ethnicity: Russian

      CasePresentingHPOs HP:0003571, HP:0012523, HP:0001531, HP:0001944, HP:0001259, HP:0001250

      (propionicacidemia, oral aversion, failure to thrive in infancy, dehydration, coma, seizures)

      HPOsFreeText feeding refusal, failure to thrive, dehydration, coma, seizures(7do). 55 IQ on Culture-Free-Test.

      CaseNotHPOs n/a

      CasePreviousTesting Diagnosis by newborn screening. PCC activity in patient fibroblasts was 0.5% of control.

      Variant NM_000532.4:c.803T>G (p.Leu268Trp), homozygous

      ClinVar n/a

      CAID CA354644558

      gnomAD not in gnomAD

      CaseAddInfo no parental consanguinity

      CasePMIDs n/a

    1. 2929 (M)

      Case2929: Male, 4 months diagnosis, Czech

      CasePresentingHPOs: HP:0001270, HP:0011344, HP:0003153, HP:0003698, HP:0002300, HP:0004484, HP:0008454 (Motor delay, Severe psychomotor retardation, Cystathioninuria, Difficulty standing, Mutism, Craniofacial asymmetry, Lumbar kyphosis)

      HPOsFreeText: Unknown total homocysteine (N/A μM/l; reference 5.1–13.9), Elevated cystathionine (5.4 μM/l; reference 0.04–0.34), Unknown total cysteine (N/A μmol/l; reference 203–369), Response to B6 treatment unknown

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CasePMIDs: 615480

      CaseAddInfo: Patient is homozygous for this mutation, Proband is born of father-daughter incest and is therefore consanguineous

      CasePreviousTesting: Cystathionine (Cysta), total cysteine (tCys), and total homocysteine (tHcy) panels

      CaseGenotypingMethod: PCR amplification of CTH coding regions and exon-intron boundaries was performed. These fragments were sequenced and aligned with a reference to find mutations. Those found were confirmed by restriction digest of 100 controls.

      Variant: NM_001902.5:c.589C>T (p.Arg197Cys)

      CAID: CA906222 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_001902.5%3Ac.589C%3ET

      gnomAD: South Asian 1.312e-4, Overall 6.378e-5 https://gnomad.broadinstitute.org/variant/1-70895477-C-T

    1. 1DBT

      Case#: Patient 1, Lebanon, Arab

      CasePresentingHPOs: Intermediate form of MSUD

      CasePreviousTesting: Previously diagnosed with MSUD by GC/MS/MS.

      CaseMethod1: PCR

      CaseMethod2: Sequencing

      CaseGenotypingMethod: Genomic DNA extracted, sequencing of BCKDHA, BCKDHB and DBT.

      Variant: NM_001918.3:c.224G>A (homozygous)

      CAID: CA341345382

      gnomAD: Not in gnomAD

      VariantEvidence: Mutation is present in lipoyl-binding domain, likely preventing binding of the lipoyl co-factor. Possibly results in a defect in the lipoyl-binding function (Alamut software analysis).

      CaseAddInfo: Same variant reported in patient 2 from the same geographical location, but unrelated according to the authors.

    1. 2

      CaseCA2: Male, 17 months death

      CasePresentingHPOs: HP:0001644, HP:0001875, HP:0001508, HP:0003535 (Dilated cardiomyopathy, Neutropenia, Failure to thrive, 3-Methylglutaconic aciduria)

      HPOsFreeText: N/A

      CaseNotHPOs: HP:0003107 (Abnormal circulating cholesterol concentration)

      NotHPOsFreeText: N/A

      CaseAddInfo: Family history of high urinary 3-MGC

      CasePreviousTesting: N/A

      CaseGenotypingMethod: The TAZ gene was PCR amplified in three fragments and directly sequenced in the mother and proband.

      Variant: NM_000116.4:c.548T>G (p.Val183Gly)

      CAID: CA415183843, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA415183843

      gnomAD: Not in gnomAD

    1. 4

      FamilyLabel Family 3

      Family3PresentingHPOs HP:0001250

      (Seizures)

      HPOsFreeText seizure onset in neonatal period from minutes after birth until 3 weeks of age. Probable PDE: either pyridoxine-responsive seizures and an affected sibling or neonatal seizures responsive to a single dose of pyridoxine with later recurrence of seizures again responsive to pyridoxine.

      FamilyNotHPOs n/a

      CountryOrigin Turkey

      Ethnicity n/a

      Race Caucasian

      Family3PreviousTesting Normal urine PA after pyridoxine treatment.


      ProbandLabel Case 4

      Case4PreviousTesting post-treatment: Pipecolic acid in plasma 31(nv 1-3.2µmol/liter). pre-treatment: CSF PA levels 4.6µmol/liter(nv 0.009–0.12), 2.3µmol/liter(nv<0.1)


      Variant NM_001182.4:c.1373G>A (p.Ser458Asn), homozygous

      ClinVar n/a

      CAID CA360721594

      gnomAD not in gnomAD

      FamilyAddInfo consanguineous, Case 3 is the sibling of Case 4 with no metabolic testing, homozygous for the same variant, with probable PDE.

      FamilyPMIDs n/a

    1. Patient description

      CaseWA: Female, 5 yrs onset, French-Canadian

      CasePresentingHPOs: HP:0002013, HP:0001944, HP:0001289, HP:0002367, HP:0001942, HP:0031962, HP:0001987, HP:0003236, HP:0001946, HP:0002919, HP:0000651, HP:0012120 (Vomiting, Dehydration, Confusion, Visual hallucinations, Metabolic acidosis, Elevated serum anion gap, Hyperammonemia, Elevated serum creatine kinase, Ketosis, Ketonuria, Diplopia, Methylmalonic aciduria)

      HPOsFreeText: Low incorporation of 14C-propionate (4.1 nmol propionate/mg protein/18 h; control mean 10.8, SD 3.7) with no response to hydroxycobalamin

      CaseNotHPOs: HP:0002151 (Increased serum lactate)

      NotHPOsFreeText: N/A

      CaseAddInfo: Parents are non-consanguineous with unremarkable family history, Treatment with carnitine and restricted protein intake normalized symptoms, Sequencing of the mother revealed Variant 2 without Variant 1 confirming compound heterozygosity

      CasePreviousTesting: Metabolic acidosis values w/ elevated anion gap (pH = 6.96, bicarbonate 3.5 mmol/L and pCO2 15.9 mm Hg, anion gap 25.5 mmol/L); Mild hyperammonemia (107 μmol/L; ref. < 50); Elevated creatine kinase (from 498 IU/L initially up to 3062 IU/L, ref. < 150); Organic acid profiles were analyzed via gas chromatography–mass spectrometry with Table 1 showing relevant organic acid values; Proband was negative for propionyl-coA carboxylase deficency (811 pmol/min/mg protein with control mean 1123, PCCA and PCCB variants were negative) and ruled out MUT/cobalamin issues as well; Fusion experiments showed negative results for mut, cblA, and cblB complementation but no increase in activity when fused with MCEE confirming the pathway blockage

      CaseGenotypingMethod: Extracted DNA from blood was amplified and three coding exons/splice site junctions of MCEE were Sanger sequenced. A deletion/duplicaiton analysis yeilded normal results. To search for an intronic sequence variant, total RNA was extracted and reverse-transcribed to confirm a 92-bp insertion between Exons 2 and 3. Resulting sequencing of this genomic area revealed a deep intronic variant that created a new consensus donor splice site that leads to a premature stop codon.

      Variant1: NM_032601.4(MCEE):c.139C>T (p.Arg47Ter)

      ClinVar: 2343, http://www.ncbi.nlm.nih.gov/clinvar/variation/2343

      gnomAD: 0.0004884, https://gnomad.broadinstitute.org/variant/2-71351575-G-A

      Variant2: NM_032601.3:c.379-644A>G

      CAID: CA892631472, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA892631472

      gnomAD: Not in gnomAD

    1. 2

      Case2: Male, 1y 7m, Chinese

      HPOsFreeText: (at 11 days) 1.69 C4 umol/L, 0.19 C4/C2, 2.38 C4/C3

      NotHPOsFreeText: normal urine isobutyrylglycine

      Case2 (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: same as group

      CaseMethod2: same as group

      CaseGenotypingMethod: same as group


      Variant: NM_014384.2:c.286G>A (p.Gly96Ser)

      ClinVar: n/a

      CAID: CA6372895

      gnomAD: 0.001453 (East Asian)


      CaseAddInfo:

    2. 7

      Case7: Male, 6m, Chinese

      CasePresentingHPOs: HP:0002248, HP:0001290, HP:0008872, HP:0002572 (haematemesis, hypotonia, feeding difficulties in infancy, recurrent vomiting)

      HPOsFreeText: (at 19 days) 1.01 C4 umol/L, 0.38 C4/C2, 1.61 C4/C3

      NotHPOsFreeText: normal urine isobutyrylglycine

      Case7 (Level 2):


      CasePreviousTesting: same as group

      CaseMethod1: same as group

      CaseMethod2: same as group

      CaseGenotypingMethod: same as group


      Variant1: NM_014384.2:c.444G>T (p.Pro148=)

      ClinVar: n/a

      CAID: CA6372946

      gnomAD: 0.0002772 (Other)

      Variant2: NM_014384.2:c.1176G>T (p.Arg392Ser)

      ClinVar: n/a

      CAID: CA6373249

      gnomAD: 0.0001088 (East Asian)


      CaseAddInfo: trans heterozygous, inherited one allele from each parent

    1. 1

      Case1 Female, 1mo diagnosis, Korean

      CasePresentingHPOs HP:0003235

      (Increased blood methionine)

      HPOsFreeText increased pre-treatment blood homocysteine and post-treatment total homocysteine, patient treated with low-methionine diet, vitamin B6, folate, vitamin B12, and betaine after diagnosis

      CaseNotHPOs HP:0001083, HP:0001249

      (Ectopia lentis, Intellectual disability)

      NotHPOsFreeText Marfan syndrome, vascular occlusion

      CasePreviousTesting pretreatment/posttreatment methionine: 1,239/123 μM(nv 7-47), pretreatment/posttreatment homocysteine: 28/0 μM(nv 0-5), posttreatment total homocysteine 144 μM(nv 5-15). Diagnosis upon neonatal screen

      CaseMethod1 PCR

      CaseMethod2 Sanger

      CaseGenotypingMethod PCR amplified all 16 coding exons of CBS gene, then direct sequenced

      Variant 1. NM_001320298.1:c.461T>A(p.Leu154Gln), 2. NM_000071.2(CBS):c.770C>T (p.Thr257Met), compound heterozygous

      ClinVar 1. n/a, 2. 188927

      CAID 1. CA410601512

      gnomAD 1. not in gnomAD, 2. MAF=0.0001396(Other), no homozygotes

      CaseAddInfo L154Q variant from father, T257M from mother. Additional R18C variant inherited from father, but protein from this SNP retains normal expression, 30-70% of enzyme activity and was found to have a 1/100 frequency in the study's control population

      CasePMIDs n/a

    1. 14

      Case 14 (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: PCR

      CaseGenotypingMethod: same as group __

      Variant1: NM_015506.2(MMACHC):c.658_660delAAG (p.Lys220del)

      ClinVar: 95707

      CAID: CA223197

      gnomAD: 0.0003071 (East Asian)


      Variant2: NM_015506.2(MMACHC):c.567dupT (p.Ile190Tyrfs*13)

      ClinVar: 556708

      CAID: CA522810899

      gnomAD: [0.0001024] (https://gnomad.broadinstitute.org/variant/1-45974604-G-GT) (East Asian)

      CaseAddInfo: proband genotype, unknown cis or trans, no phenotypic info, sibling (fetus) carrier for p.K220del maternal variant

    2. 2

      Case 2 (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: PCR

      CaseGenotypingMethod: same as group


      Variant1: NM_015506.2(MMACHC):c.217C > T

      ClinVar: 203825

      CAID: CA312728

      gnomAD: 0.00005560 (East Asian)


      Variant2: NM_015506.2(MMACHC):c.658_660delAAG

      ClinVar: 95707

      CAID: CA223197

      gnomAD: 0.0003071 (East Asian)


      CaseAddInfo: proband genotype, unknown cis or trans, not any phenotypic info given, sibling (fetus) carrier of p.R73X maternal variant

    3. 15

      Case 15 (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: PCR

      CaseGenotypingMethod: same as group

      __

      Variant1: NM_015506.2(MMACHC):c.394C > T (p.Arg132Ter)

      ClinVar: 1423

      CAID: CA251787

      gnomAD: 0.0007190 (South Asian)


      Variant2: NM_015506.2(MMACHC):c.615C > A (p.Tyr205Ter)

      ClinVar: 558292

      CAID: CA340133688

      gnomAD: 0.0006427 (East Asian)


      CaseAddInfo: proband genotype, unknown cis or trans, no phenotypic info, sibling (fetus) carries both variants

    1. Case history and genetic analysis

      CaseKO: Male, 22 yrs report, Serbia

      CasePresentingHPOs: HP:0002076, HP:0002017, HP:0000505, HP:0002357, HP:0003474, HP:0004302, HP:0001269, HP:0012229, HP:0011288, HP:0002321, HP:0000622 (Migraine, Nausea and vomiting, Visual impairment, Dysphasia, Sensory impairment, Functional motor deficit, Hemiparesis, CSF pleocytosis, EEG with parietal sharp slow waves, Vertigo, Blurred vision)

      HPOsFreeText: Mechanosensitivity

      CaseNotHPOs: HP:0011182, HP:0001251, HP:0001250 (Interictal epileptiform activity, Ataxia, Seizure)

      NotHPOsFreeText: N/A

      CaseAddInfo: No evidence of headache attacks with focal neurological deficits in any other family member, but the patient’s father was found to suffer from migraine without aura

      CasePreviousTesting: Responsive to treatment with ibuprofen; Mild head trauma is a trigger; Neuroimaging during attacks was normal; Screen for variants in CACNA1A, ATP1A2, SCN1A, and PRRT2 was negative

      CaseGenotypingMethod: All exons and exon-intron boundaries of the SLC1A3 gene were seuqenced and a variant was found that segregates with the phenotype.

      Variant: NM_004172.5:c.1159A>C (p.Thr387Pro)

      CAID: CA359482299, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA359482299

      gnomAD: Not in gnomAD

    1. Case report

      CaseBH: Male, Somalia, 8 yrs report

      CasePresentingHPOs: HP:0003026, HP:0001511, HP:0000973, HP:0008936, HP:0000023, HP:0008780, HP:0000519, HP:0000639, HP:0011493, HP:0001263, HP:0001999, HP:0000337, HP:0000325, HP:0000494, HP:0000160, HP:0000977, HP:0001181, HP:0002119, HP:0005116 (Short long bone, Intrauterine growth retardation, Cutis laxa, Truncal hypotonia, Inguinal hernia, Congenital bilateral hip dislocation, Developmental cataract, Nystagmus, Central opacification of the cornea, Global developmental delay, Abnormal facial shape, Broad forehead, Triangular face, Downslanted palpebral fissures, Narrow mouth, Soft skin, Adducted thumb, Ventriculomegaly, Arterial tortuosity)

      HPOsFreeText: At age 8 years, his height was 96 cm (Z=−5.8) and weight was 11.6 kg (Z=−7.26); Head circumference was 45.4 cm, (Z=−5.0) which is the 50th centile for a 10-month-old boy; Walked with support

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CaseAddInfo: Parents are consanguineous fourth cousins, Had an older sister and younger brother who were developmentally appropriate and well grown

      CasePreviousTesting: N/A

      CaseGenotypingMethod: PYCR1 and ALDH18A1 were Sanger sequenced in the proband which revealed a single variant. Chromosomal SNP microarray showed no regions of homozygosity or any other deletions or duplications. Whole Exome Sequencing of genomic DNA from the proband was performed for confirmation again only revealing the single heterozygous missense variant in ALDH18A1. Copy-number analysis was performed and identified no significant variation. Sequencing of the parents revealed a de novo inheritance pattern.

      Variant: NM_002860.3:c.377G>A (p.Arg126His)

      CAID: CA377706756 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA377706756

      gnomAD: Not in gnomAD

    1. 3

      Case1873(W.C.) Male, 37yo report, Irish

      CasePresentingHPOs HP:0002625, HP:0000766, HP:0002942, HP:0006682, HP:0005625, HP:0002353

      (Deep vein thrombosis, Sternal anomaly, Thoracic kyphosis, Ventricular extrasystoles, Osteoporosis of vertebrae, EEG abnormality)

      HPOsFreeText Patient had single episode of deep vein thrombosis of left leg at 30yo. No further clinical sequelae related to homocystinuria.

      (PMID: 20329304): Patient was born normally at 36wks gestation weighing 2.9kg. By 9 and half years old he was well developed and nourished, mentally normal at IQ 93. He did have pronounced malar flush, some grey hair of normal texture, slightly depressed sternum, mild kyphosis of upper thoracic spine. Exam of major systems was normal save for occasional ventricular extrasystole. Roengenogram showed marked osteoporosis of spine, but normal long bones. EEG showed non-specific diffuse abnormality.

      CaseNotHPOs HP:0001083

      (Lens dislocation)

      NotHPOsFreeText lenses were found to not be displaced upon exam at 9 and a half years old.

      CasePreviousTesting Plasma homocysteine was 450μM pretreatment. Pyroxidine treatment reduced those levels to trace amounts. In patient fibroblasts, no CBS protein was detect on Western blot and CBS assay detected no activity. (PMID: 20329304): "Full hemogram, routine urine analysis, liver function tests, serum ion and iron-binding capacity, plasma magnesium, serum calcium, inorganic phosphate, fasting blood sugars, blood urea nitrogen, and bone marrow examination were all normal". Heavy homocysteine spot shown on chromatogram of urinary amino acids.

      CaseMethod1 PCR

      CaseMethod2 Sanger

      CaseGenotypingMethod Created a bacteria expression system in E.coli by substituting one of three fragments of (PCR amplified)patient cDNA into WT CBS sequence already subcloned in expression plasmids. Bacteria were screened based on which ones did not have CBS activity. Those that did not have activity were thought to have LOF variants in CBS. Plasmids containing the inactivating fragments, one cut with NcoI/XmaI and another cut with Bpu1102/BstX, were sequenced.

      Variant 1. NM_000071.2:c.715G>A (p.Glu239Lys),

      1. NM_000071.2:c.233C>G (p.Pro78Arg);3. NM_000071.2:c.306G>C (p.Lys102Asn) - 2&3 in cis, compound heterozygous

      ClinVar 1. n/a, 2. 188988;3. 188989

      CAID 1. CA410600501

      gnomAD 1. not in gnomAD, 2. MAF=0.0001631(Other), no homozygotes, 3. MAF=0.0001630(Other), no homozygotes

      CaseAddInfo Mother had edema of both legs with no other features of pre-eclampsia during the last six weeks of pregnancy.

      CasePMIDs 20329304

    1. CHN2.1

      CaseCHN2.1: Canada, White

      CasePresentingHPOs: HP:0008353 (Neutral hyperaminoaciduria)

      HPOsFreeText: N/A

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CaseAddInfo: Variants segregate with the disease

      CasePreviousTesting: Hartnup aminoaciduria profile was confirmed by ion exchange high performance liquid chromatography

      CaseGenotypingMethod: All SLC6A19 exons and flanking introns were directly amplified and sequenced from genomic DNA.

      Variant1: NM_001003841.3:c.532C>T (p.Arg178Ter)

      CAID: CA3182753, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA3182753

      gnomAD: 0.0004414, https://gnomad.broadinstitute.org/variant/5-1212468-C-T

      Variant2: NM_001003841.3:c.1213G>A (p.Glu405Lys)

      CAID: CA3183103, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA3183103

      gnomAD: 0.0001203, https://gnomad.broadinstitute.org/variant/5-1219057-G-A

    2. CHN1.1

      CaseCHN1.1: Canada, White

      CasePresentingHPOs: HP:0008353 (Neutral hyperaminoaciduria)

      HPOsFreeText: N/A

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CaseAddInfo: Variants segregate with the disease, Has a sibling with the same variant and amino acid profile

      CasePreviousTesting: Hartnup aminoaciduria profile was confirmed by ion exchange high performance liquid chromatography;

      CaseGenotypingMethod: All SLC6A19 exons and flanking introns were directly amplified and sequenced from genomic DNA.

      Variant1: NM_001003841.3:c.196G>A (p.Gly66Arg)

      CAID: CA359061114 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA359061114

      gnomAD: Not in gnomAD

      Variant2: NM_001003841.3:c.982C>T (p.Arg328Cys)

      CAID: CA3182972, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA3182972

      gnomAD: 0.0002479, https://gnomad.broadinstitute.org/variant/5-1216767-C-T

    1. Patient 9

      Case9: Male, Turkey, 24 yrs report,

      CasePresentingHPOs: HP:0002251, HP:0001321, HP:0001161, HP:0025356, HP:0002474, HP:0000708, HP:0001488, HP:0002317, HP:0000646, HP:0000486 (Aganglionic megacolon, Cerebellar hypoplasia, Hand polydactyly, Psychomotor retardation, Expressive language delay, Behavioral abnormality, Bilateral ptosis, Unsteady gait, Strabismus)

      HPOsFreeText: Dysgnathia

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CaseAddInfo: Proband is homozygous, Parents are consanguineous, cDNA amplification of the exons 8 and 9 in this patient revealed an insertion of 64 base pairs due to the use of a cryptic donor site leading to a premature stop codon and a likely null allele; Proband has two healthy sisters

      CasePreviousTesting: Patient fibroblasts were analyzed for mutations in SLC25A21 and activities of KATII with no abnormalities; A metabolic work-up revealed alpha-ketoadipic aciduria and alpha-aminoadipic aciduria; A non-verbal intelligence test yielded a slightly decreased value; A single metabolic decompensation in adulthood was ascribed to Helicobacter pylori and its eradication improved the patient’s well-being.

      CaseGenotypingMethod: All 17 exons and flanking intronic sequences of DHTKD1 were Sanger sequenced.

      Variant: NM_018706.6:c.1671+1G>A

      CAID: CA5407905 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_canonicalid?canonicalid=CA5407905

      gnomAD: 0.0001399, https://gnomad.broadinstitute.org/variant/10-12139996-G-A

    1. Patient 2

      Case2 unknown sex, Netherlands, Dutch

      CasePresentingHPOs HP:0001250, HP:0001263

      (Seizures, Developmental delay)

      HPOsFreeText Seizures ceased upon administration of pyridoxine. (PMID:16159904:) 1st seizure at 4do, first administered pyridoxine 6mo, age at trial 1.7yr, initial dose:100mg, maintenance dose:100mg/day, delayed development(PMID:17088338:) Definite="recurrent (two or more) seizures of any type that cease within seven days of the administration of oral pyridoxine (usual dose, 30 mg/ kg/day; minimum dose, 15 mg/kg/day; maximum dose, 1000 mg/kg/day) or within 30 minutes of intravenous pyridoxine (usual dose, 100 mg; minimum dose, 50 mg), that recur when pyridoxine supplementation is withdrawn, and that cease again when pyridoxine is given as above"

      CaseNotHPOs n/a

      NotHPOsFreeText intrauterine seizures

      CasePreviousTesting PDS confirmed metabolically: α‐AASA urine 4.7(nv <1mmol/mol cr), α‐AASA plasma 0.9(nv <0.2μmol/l), pipecolic acid urine 0.27(nv 0.55-24.1mmol/mol cr <6mo, 0.01–1.54mmol/mol cr >6 mo) pipecolic plasma 5.8(nv 3.75-10.8μmol/l <1wk, 0.7-2.46μmol/l >1wk)

      Variant 1. NM_001202404.1:c.1321T>A (p.Cys441Ser), 2. NM_001182.4(ALDH7A1):c.834G>A (p.Val278=)

      ClinVar 1. n/a, 2. 18002

      CAID 1. CA360721136

      gnomAD 1. not in gnomAD, 2. not in gnomAD(C and not G at that position?)

      CaseAddInfo Parents heterozygous for either allele=variants in trans in the patient. Two unaffected siblings, one with neither variant and the other with one copy of the p.Cys441Ser variant

      CasePMIDs 17088338 , 16159904

    1. c.286delGAA

      Case# PB3, Saudi Arabia

      CasePresentingHPOs HP:0000707, HP:0003011, HP:0025031, HP:0001939, HP:0002715

      CasePreviousTesting Blood spot newborn screen/presented symptoms in Hospital

      CaseMethod1 PCR

      CaseGenotypingMethod PCR of coding exons of BCKDHA (9 exons), BCKDHB (11 exons) DBT (11 exons) and DLD (14 exons).

      Variant NM_000056.3:c.286del

      CAID CA658820633

      VariantEvidence null

      CaseAddInfo consanguineous family

    2. c.197G > C

      Case# PB2, Saudi Arabia

      CasePresentingHPOs HP:0000707, HP:0003011, HP:0025031, HP:0001939, HP:0002715

      CasePreviousTesting Blood spot newborn screen/presented symptoms in Hospital

      CaseMethod1 PCR

      CaseGenotypingMethod PCR of coding exons of BCKDHA (9 exons), BCKDHB (11 exons) DBT (11 exons) and DLD (14 exons).

      Variant NM_000056.3:c.197G>C

      CAID CA364658947

      VariantEvidence none

      CaseAddInfo consanguineous family

    1. 24

      Case24 sex unknown, Spain

      CasePresentingHPOs HP:0000707

      (Neurological abnormality)

      HPOsFreeText Clinical onset was "insidious," involving slowly progressive psychomotor delay, dystonic postures, lethargy, or macrocephaly. Phenotypes defined as "slight," entailing minimal neurological signs and an otherwise normal life. Diagnosed by routine GC-MS organic acid analysis in urine. There was high excretion of glutarate and 3-hydroxyglutarate with glutarate excretion being higher than that of 3-hydroxyglutarate.

      CaseNotHPOs n/a

      NotHPOsFreeText n/a

      CasePreviousTesting GC-MS measured glutarate of 1673(nv 2–10 mmol/mol creatinine) and 3-OH-glutarate 795(nv 2–14 mm/mol creatinine). In patient fibroblasts, %GCD activity was <0.5.

      CaseMethod1 SSCP

      CaseMethod2 Sanger

      CaseGenotypingMethod PCR amplified and SSCP screened 11 exons and intron boundaries of GCDH gene. Confirmed variants with Sanger sequencing and restriction digest. The A304T variant destroys an AluI restriction site. Thus, while the patient's DNA fragments would not cleave, control fragments would be cleaved. The L309W variant creates an EcoP15 site. This would lead to cleaved patient DNA fragments and uncleaved control fragments.

      Variant 1. NM_000159.3(GCDH):c.910G>A (p.Ala304Thr), 2. NM_000159.3:c.926T>G (p.Leu309Trp), compound heterozygous

      ClinVar 1. 554907, 2. n/a

      CAID 2. CA404319538

      gnomAD 1. MAF=0.00006163(African), no homozygotes, 2. MAF= 0.000008816(European(non-Finnish)), no homozygotes CaseAddInfo n/a

      CasePMIDs n/a

    1. 16

      Patient16: Group 3

      CasePresentingHPOs: same as group 3

      CasePreviousTesting: same as group 3

      CaseGenotypingMethod: same as group 3

      Variant1: NM_001159508.1:c.149G>C (p.Arg50Thr) listed in paper as (p.Arg21Pro)

      CAID: CA391743853, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA391743853

      gnomAD: n/a

      Variant2: NM_002225.4:c.851G>A

      CAID: CA7480763, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA7480763

      **In ClinVar as: NM_002225.3(IVD):c.860G>A (p.Arg287Gln), https://www.ncbi.nlm.nih.gov/clinvar/variation/555453/ **

      gnomAD: 0.00001770, http://gnomad.broadinstitute.org/variant/15-40707154-G-A

    2. 18

      Patient18: Group 3

      CasePresentingHPOs: same as group 3

      CasePreviousTesting: same as group 3

      CaseGenotypingMethod: same as group 3

      Variant1: NM_002225.3:c.1136T>C (p.p.Ile349Thr) **listed in paper as (p.Phe350Ser)

      CAID: CA391723904, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA391723904

      gnomAD: n/a

      Variant2: IVS3+5G>T no ClinVar or CAID

    1. 4.4. Tafazzin functionality

      ExperimentName: TAZ Function in Patient Fibroblasts

      PatientCell: CL:0000057 (Fibroblast)

      GeneFunction: GO:0003841 (1-acylglycerol-3-phosphate O-acyltransferase activity)

      GeneAlteration: Fibroblasts were utilized from frozen tissue samples that were taken from 14 Barth Syndrome probands and compared to age-matched controls.

      FunctionalEvidence: Several relevant tafazzin slice variants (full transcript, -ex5, and -ex7) were expressed in human BTHS fibroblasts and the MLCL/CL ratio was compared to age-matched controls and the previous results from the fibroblasts themselves. This ratio is important as the amount of cardiolipin (CL) conversion by tafazzin is crucial to the disease progress and observable phenotypes. Overall, the ratio observed in fibroblasts alone was significantly higher than controls (~1.1, reference 0.12). The expression of tafazzin splice variants did rescue some of the ratio, although only the preumed active variant lacking exon 5 showed significant decrease of the ratio (~0.5).

      FAVariant1: NM_000116.5(TAZ):c.153C>G (p.Tyr51Ter)

      ClinVar: 11101, https://www.ncbi.nlm.nih.gov/clinvar/variation/11101/

      FAVariant2: NM_000116.4:c.170G>T (p.Arg57Leu)

      CAID: CA415179752, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA415179752

      FAVariant3: NM_000116.4:c.590G>T (p.Gly197Val)

      CAID: CA415184091, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA415184091

      FAVariant4: NM_000116.5(TAZ):c.280C>T (p.Arg94Cys)

      ClinVar: 202092, https://www.ncbi.nlm.nih.gov/clinvar/variation/202092/

    1. We evaluated 16 patients with IVA, including 3 pairs of siblings

      Patient4: Female, 3yo sibling to patient 5

      CasePresentingHPOs:

      HPOsFreeText: Asymptomatic, C5 (DBS) = 4.0 μmol l−1, IVA incorp (%) = 80, IVG in urine mmol permol creatinine = 242, Ammonium (μmol l−1) = 31, pH = 7.37, Protein intake (g kg−1 per day) = 1.5, treated with carnitine supplements, PDI/IQ in follow-up = 92

      CaseNotHPOs: HP:0011968, HP:0002013, HP:0001944, HP:0001254, HP:0001259

      (poor feeding, vomiting, dehydration, lethargy, coma)

      NotHPOsFreeText: sweaty feet odor

      CaseAddInfo: Diagnosed with NBS, diagnosed at 26 days old

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_002225.4(IVD):c.1205T>C (p.Ile402Thr)

      ClinVar: 529433, https://www.ncbi.nlm.nih.gov/clinvar/variation/529433/

      gnomAD: n/a

      Variant2: NM_001159508.1:c.500T>C

      CAID: CA391717541, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA391717541

      gnomAD: n/a

    1. Table 1

      Case# P1, 4day onset, Turkish

      CasePresentingHPOs HP:0002151, HP:0001946, HP:0001942, HP:0001987

      CasePreviousTesting negative for NAGS and CPS1 genes.

      CaseGenotypingMethod sequence analysis of coding exons, including flanking intronic regions of CA5A and CA5B, was performed.

      Variant NM_001739.1:c.123G>A

      CAID CA397038622

      VariantEvidence truncated protein

      CaseAddInfo consanguineous

    1. Table 2

      Case10: Male, Ecuador

      CasePresentingHPOs: HP:0001290, HP:0003324, HP:0002093, HP:0011968, HP:0001283, HP:0001561, HP:0001558, HP:0000602, HP:0001622, HP:0001371, HP:0001623, HP:0002804 (Generalized hypotonia, Generalized muscle weakness, Respiratory insufficiency, Feeding difficulties, Bulbar weakness, Polyhydramnios, Decreased fetal movements, Ophthalmoplegia, Preterm delivery, Contractures, Breech presentation, Arthrogryposis)

      HPOsFreeText: Bilateral femoral fractures

      CaseNotHPOs: HP:0001627 (Cardiac abnormality)

      NotHPOsFreeText: N/A

      CaseAddInfo: Severe congenital myopathy, Deceased in 6 weeks

      CasePreviousTesting: N/A

      CaseGenotypingMethod: After LMOD3 was identified as a potential causal gene, bidirectional Sanger sequencing was performed on DNA in genetically unresolved patients using PCR amplification covering 3 exons.

      Variant1: NM_198271.4:c.976G>C (p.Gly326Arg)

      CAID: CA353473660 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_198271.4%3Ac.976G%3EC

      gnomAD: Not in gnomAD

      Variant2: NM_198271.4:c.1372C>T (p.Gln458*)

      CAID: CA353470920 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_198271.4%3Ac.1372C%3ET

      gnomAD: Not in gnomAD

    2. Table 2

      Case6: Female, Japan, Asian

      CasePresentingHPOs: HP:0001290, HP:0003324, HP:0002093, HP:0011968, HP:0001283, HP:0003798, HP:0001561, HP:0001558, HP:0001789, HP:0000252, HP:0001622, HP:0001371 (Generalized hypotonia, Generalized muscle weakness, Respiratory insufficiency, Feeding difficulties, Bulbar weakness, Nemaline bodies, Polyhydramnios, Decreased fetal movement, Hydrops fetalis, Microcephaly, Preterm delivery, Contractures)

      HPOsFreeText: Atrophic myofibers

      CaseNotHPOs: HP:0001627 (Cardiac abnormality)

      NotHPOsFreeText: N/A

      CaseAddInfo: Severe congenital myopathy, Alive at 10 months

      CasePreviousTesting: N/A

      CaseGenotypingMethod: After LMOD3 was identified as a potential causal gene, bidirectional Sanger sequencing was performed on DNA in genetically unresolved patients using PCR amplification covering 3 exons.

      Variant: NM_198271.4:c.349C>T (p.Gln117*)

      CAID: CA353477271 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_198271.4%3Ac.349C%3ET

      gnomAD: Not in gnomAD

    3. Table 2

      Case3: Female, Portugal

      CasePresentingHPOs: HP:0001290, HP:0003324, HP:0002093, HP:0011968, HP:0001283, HP:0002804, HP:0001558, HP:0001561, HP:0001371 (Generalized hypotonia, Generalized muscle weakness, Respiratory insufficiency, Feeding difficulties, Bulbar weakness, Decreased fetal movement, Polyhydramnios, Contracture)

      HPOsFreeText: N/A

      CaseNotHPOs: HP:0001627 (Cardiac abnormality)

      NotHPOsFreeText: N/A

      CaseAddInfo: Severe congenital myopathy, Deceased in neonatal period

      CasePreviousTesting: N/A

      CaseGenotypingMethod: After LMOD3 was identified as a potential causal gene, bidirectional Sanger sequencing was performed on DNA in genetically unresolved patients using PCR amplification covering 3 exons.

      Variant: NM_198271.4:c.154del (p.Met52*)

      CAID: CA909810717 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_198271.4%3Ac.154delA

      gnomAD: Not in gnomAD

    1. Case Report

      CaseAN: Male, 78 yrs report, Germany, White

      CasePresentingHPOs: HP:0003774, HP:0001638, HP:0000822, HP:0002099, HP:0012125, HP:0001297, HP:0002134, HP:0002549, HP:0000738, HP:0000739, HP:0000746, HP:0002322, HP:0002172, HP:0012120 (Stage 5 chronic kidney disease, Cardiomyopathy, Hypertension, Asthma, Prostate cancer, Stroke, Abnormality of the basal ganglia, Deficit in phonologic short-term memory, Hallucinations, Anxiety, Delusions, Resting tremor, Postural instability, Methylmalonic aciduria)

      HPOsFreeText: N/A

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CaseAddInfo: Mother had dementia, Proband is diagnosed with Parkinson's disease, Sanger sequencing confirmed compound heterozygous as unaffected sons are heterozygous for one variant each

      CasePreviousTesting: Montreal Cognitive Assessment (MoCA) score of 17/30 in 2013; Mild MMA-uria, together with increased plasma levels of propionyl-carnitine, was demonstrated in 2016 via metabolic investigation (values in Table 1)

      CaseGenotypingMethod: Whole genome sequencing data was analyzed using a pipeline restricted to 681 genes known to cause IEM. Heterozygous mutations in MCEE were identified.

      Variant1: NM_032601.4(MCEE):c.139C>T (p.Arg47Ter)

      ClinVar: 2343, http://www.ncbi.nlm.nih.gov/clinvar/variation/2343

      gnomAD: 0.0004884, https://gnomad.broadinstitute.org/variant/2-71351575-G-A

      Variant2: NM_032601.3:c.419del (p.Lys140Argfs*6)

      CAID: CA1702578, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA1702578

      gnomAD: 0.00007076, https://gnomad.broadinstitute.org/variant/2-71337211-CT-C

    1. A male patient

      Case# P1, Male, Chinese, 5 months

      CasePresentingHPOs HP:0006986, HP:0002373, HP:0008947, HP:0001249

      CaseMethod1 PCR

      CaseGenotypingMethod PCR of sevon exons of QDPR gene

      Variant NM_000320.2:c.661C>T(p.R221X), NM_000320.2:c.515C>T(p.P172L)

      CAID CA2868005, CA2868085

      gnomAD (Latino) 0.00002978, (Ashkenazi Jewish) 0.0001019

      VariantEvidence null

      CasePMIDs 19099731

    1. The patient

      Case1: Male, 15 months onset, Iran

      CasePresentingHPOs: HP:0006579, HP:0001324, HP:0001336, HP:0000639, HP:0002134, HP:0002282, HP:0002453, HP:0002540, HP:0002463, HP:0006801, HP:0001252, HP:0011443, HP:0001251, HP:0001310, HP:0000565, HP:0001510 (Neonatal jaundice, Muscle weakness, Myoclonus, Nystagmus, Abnormality of the basal ganglia, Heterotopia, Abnormality of the globus pallidus, Inability to walk, Language impairment, Hyperactive deep tendon reflexes, Muscular hypotonia, Abnormality of coordination, Ataxia, Dysmetria, Esotropia, Growth delay)

      HPOsFreeText:

      CaseNotHPOs: HP:0012443, HP:0012447 (Abnormality of brain morphology, Abnormal myelination)

      NotHPOsFreeText:

      CaseAddInfo: No parental consanguinity,

      CasePreviousTesting: Plasma amino acids and plasma acylcarnitine profile were normal. The organic acid in the urine showed an elevated 3‐hydroxyisovaleric acid (110 mmol/mol creatinine, normal <44 mmol/mol creatinine). Serum biotinidase activity was normal. Blood lactate and ammonia were normal in repeated measurements.

      CaseGenotypingMethod: Patient had the IVD exons and exon-intron boundaries analyzed using PCR/Sanger sequencing to follow up on suspected IVA, with no variants found. Whole Exome Sequencing was performed to determine the correct genetic cause of the disorder by evaluating all known exons and their flanking regions. This found two heterozygous missense mutations in HIBCH consistent with the diagnosis. Trio PCR/Sanger sequencing confirmed parental heterozygosity and the variants in the patient.

      Variant1: NM_014362.3:c.641C>T (p.Thr214Ile)

      CAID: CA349890265 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_014362.3%3Ac.641C%3ET

      gnomAD: Not in gnomAD

      Variant2: NM_014362.3:c.913A>G (p.Thr305Ala)

      CAID: CA62635843 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_014362.3%3Ac.913A%3EG

      gnomAD: European (Non-Finnish) 1.767e-5, Overall 7.978e-6 https://gnomad.broadinstitute.org/variant/2-191077780-T-C

    1. a

      CaseST-8: Female, 1 day onset, Germany

      CasePresentingHPOs: HP:0006579, HP:0001643, HP:0001410, HP:0001319, HP:0006236, HP:0001786 (Prolonged neonatal jaundice, Patent ductus arteriosus, Decreased liver function, Neonatal hypotonia, Slender metacarpals, Narrow foot)

      HPOsFreeText: N/A

      CaseNotHPOs: HP:0001250 (Seizure)

      NotHPOsFreeText: N/A

      CaseAddInfo: Family is non-consanguineous, Proband is compound heterozygous for these variants

      CasePreviousTesting: See Group

      CaseGenotypingMethod: See Group

      Variant1: NM_001123.3:c.893C>A (p.Ala298Asp)

      CAID: CA377399006, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA377399006

      gnomAD: Not in gnomAD

      Variant2: NM_001123.3:c.925C>T (p.Gln309Ter)

      CAID: CA377398330, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA377398330

      gnomAD: Not in gnomAD

    2. e

      CaseST-6: Male, 1 day onset, Morocco

      CasePresentingHPOs: HP:0006579, HP:0001249, HP:0001270, HP:0001324, HP:0004322, HP:0000256, HP:0000316, HP:0006236, HP:0001786, HP:0008070, HP:0000708, HP:0002355, HP:0003202, HP:0002071 (Prolonged neonatal jaundice, Intellectual disability, Motor delay, Muscle weakness, Short stature, Macrocephaly, Hypertelorism, Slender metacarpals, Narrow foot, Sparse hair, Behavioral abnormality, Difficulty walking, Skeletal muscle atrophy, Abnormality of extrapyramidal motor function)

      HPOsFreeText: N/A

      CaseNotHPOs: HP:0001250 (Seizure)

      NotHPOsFreeText: N/A

      CaseAddInfo: Family is consanguineous, Proband is homozygous for the variant

      CasePreviousTesting: See Group

      CaseGenotypingMethod: See Group

      Variant: NM_001123.3:c.685_687delinsCC (p.Thr229ProfsTer16)

      CAID: CA1139768931, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA1139768931

      gnomAD: Not in gnomAD

    1. Table 1

      Case4: Female, 2 wks at initation of follow up, European ancestry

      HPOsFreeText: NBS C4-acylcarnitine 2.0 umol/L, Plasma C4-acylcarnitine 1.52 umol/L

      CaseAddInfo: no data for urine excretion, unremarkable clinical condition

      Case4 (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: same as group

      CaseMethod2: same as group

      CaseGenotypingMethod: same as group


      Variant1: NM_014384.2:c.443C>T (p.Pro148Leu)

      ClinVar: n/a

      CAID: CA6372945

      gnomAD: not in gnomAD


      Variant2: NM_014384.2(ACAD8):c.455T>C (p.Met152Thr)

      ClinVar: 5355

      CAID: CA117433

      gnomAD: 0.0001395 (European Non-Finnish)


      CaseAddInfo: compound heterozygote, indicated alleles 1 and 2 but not specified maternal and paternal, potential splice site variant of ACAD8 at exon3 (+3A>G)

    2. Table 1

      Case3a: Male, 5d at initiation of follow up, East Indian Ancestry, sibling of Case 3b (family 1)

      HPOsFreeText: NBS C4-acylcarnitine 2.4 umol/L, Plasma C4-acylcarnitine 1.14 umol/L, in vitro probe isoC4-acylcarnitine 0.133 umol/ g protein,

      NotHPOsFreeText: normal urine isobutyrylglycine ug/mg creatinine

      CaseAddInfo: unremarkable clinical condition

      Case3a (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: same as group

      CaseMethod2: same as group

      CaseGenotypingMethod: same as group


      Variant: NM_014384.2(ACAD8):c.867C>A (p.His289Gln)

      ClinVar: 5358

      CAID: CA117441

      gnomAD: not in gnomAD


      CaseAddInfo: homozygous mutations

    1. 18804

      Case# 18804, Spanish, 3yo report

      CaseHPOs asymmptomatic

      Variant NM_000709.3:c.647C>T, NM_000709.3:c.889C>T

      CAID CA9461230(c.647), CA9461294(889)

      gnomAD c.647=0.0001332(African), 0.00002463(Overall), c.889=0.00006534(African), 0.00001624(Overall)

      VariantEvidence reduced BCKD activity to 30% of normal in patient fibroblasts

      CaseAddInfo in trans

    2. 20493

      Case# 20493, Spanish, 1yo reported

      CasePresentingHPOs HP:0008344

      CasePreviousTesting categorized into classical and variant phenotypes based on BCKD deficiency assessed by measuring the L-[1-14C] leucine decarboxylation rate by intact cells in absence of BCKD kinase inhibitors (Duran, et al., 1978), plasma amino acid levels, and mode of clinical presentation

      CaseMethod1 Direct Sequencing

      CaseMethod2 PCR

      CaseGenotypingMethod direct sequencing of PCR fragments obtained after amplification of the entire coding sequence of BCKDHA, BCKDHB or DBT genes. sequenced both strands (forward and reverse) of corresponding exons and their intronic flanking sequence for confirmation.

      Variant NM_000709.3:c.757G>A, NM_000709.3:c.848G>A, NM_000709.3:c.898G>A

      CAID CA9461255(757), [CA406013082(848)&CA406013351(898)]

      gnomAD c.757=0.00006681(European(Non-Finnish)), 0.00003236(Overall)

      VariantEvidence Patient fibroblasts had <1% of normal BCKD activity

      CaseAddInfo parents genotypes confirmed (in trans)

    1. CaseLE12: Female, 23 yrs report

      CasePresentingHPOs: HP:0002725 (Systemic lupus erythematosus)

      HPOsFreeText: N/A

      CaseNotHPOs: N/A

      NotHPOsFreeText: N/A

      CaseAddInfo: Variant 1 homozygous, with variant 2 in-cis with one copy confirmed via parental testing

      CasePreviousTesting: Specific plasma MMA levels, urine MMA levels, urine MA levels, and MMA/MA ratio available in Table 2

      CaseGenotypingMethod: See Group

      Variant1: NM_001243279.3:c.1553C>A (p.Ala518Asp)

      CAID: CA8238286, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA8238286

      gnomAD: 0.00006153, https://gnomad.broadinstitute.org/variant/16-89212397-C-A

      Variant2: NM_001243279.3:c.473C>T (p.Pro158Leu)

      CAID: CA8237662, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA8237662

      gnomAD: 0.0002823, https://gnomad.broadinstitute.org/variant/16-89167562-C-T

    1. GM-649

      Case# GM-649, M

      CaseMethod1 Sanger

      CaseMethod2 PCR

      Variant NM_000709.3:c.284C>A(p.Pro95His)

      CAID CA406005099(p.Pro95His)

      gnomAD p.Pro95His=0.0003330(African), 0.00002887(Overall)

      VariantEvidence total BCKDH activity (4) in fibroblast extracts from the patient (GM649) is < 10% of normal (Table 1) in 2703538

      CaseAddInfo examined patient fibroblasts here and in the previous article

      CasePMIDs 2703538

    1. Case 5

      Case# Case 5, M, Chinese, 4day onset

      CasePresentingHPOs HP:0008344, HP:0040168, HP:0008947, HP:0011968

      CasePreviousTesting Tested blood aa levels with liquid chromatography-mass spectrum spectrometry, several branched chain amino acids were overly abundant. Whole exome targeted capture sequencing was applied for the mutation screening of the suspicious patients. A total of 712 genes associated with inherited metabolic diseases were selected and their coding regions were captured.

      CaseMethod1 Whole Exome

      CaseMethod2 Sanger

      CaseGenotypingMethod validated whole exome findings with sanger and qPCR.

      Variant NM_000056.3:c.863C>A(p.Ala288Asp), ?

      CAID CA364660141 (miss), wait for follow up (exon del)

    1. Case: Patient C, 11 years, female CaseHPOs: HP:0003235, HP:0011098, Hypermethioninemia, speech dyspraxia

      CaseHPOsFreeText: “pronounced hypermethioninaemia on neonatal screening”, cleft lip and palate; Hypermethioninaemia has persisted; unpleasant odor with high blood concentrations of mercaptans; fine nystagmus, dysdiadochokinesis, and increased tendon reflexes led to brain MRI and CT at age 11 years which showed demyelination, calcification of basal ganglia, IQ 87; normal myelination and all symptoms resolved after 12 months treatment with S-adenosylmethionine toluene sulphonate.

      CaseNotHPOs: Homocystine was not detected in plasma or urine,normal liver function tests.

      CasePreviousTesting: Plasma methionine 600–1,400 umol/L; otherwise normal amino acids. 5-methyl tetrahydrofolate 329, 232 nmol/L (normal 23-170, mean 85+/-41), normalized after 12 months on S-adenosylmethionine toluene sulphonate; S-adenosylmethionine 70, 87 nmol/L (normal 172-450, mean 255 +/-69), improved but still low after 12 months on S-adenosylmethionine toluene sulphonate.

      Variant: c.826dupG (homozygous)

      ClinVar: N/A

      CAID: CA5576692

      gnomAD: The highest population minor allele frequency in gnomAD is 0.00003298 (S. Asian); no homozygotes in any population.

      VariantEvidence: When the variant was expressed in bacteria, the amount and size of the protein was reduced on Western blot, and there was no detectable MAT1A activity.

      CaseAddInfo: The mother is heterozygous for the variant; DNA testing results for the father are not available.

      CasePMIDs: 1683972

      Points: 2 points. This patient is homozygous for a frameshift variant in MAT1A. When the variant was expressed in bacteria, there was no detectable MAT activity. The highest population minor allele frequency in gnomAD is 0.00003298 (S. Asian); no homozygotes in any population.